Investing News

Life Science Investing News Stocks

Solarvest BioEnergy

Producing The World’s Only Plant-based Organic Certified Omega -3

Overview

The global nutraceuticals market is expected to grow at a CAGR of 9.3 percent, with the potential to reach a market value of $658.11 billion by 2028. Nutraceuticals refer to medicinally or nutritionally functional consumables that include herbal remedies, nutritional supplements and fortified foods, among many other things. The nutraceuticals market was valued at US$320 billion in 2020 alone.

Among all nutraceutical products, Omega-3 fatty acids products are the most popular around the world. Omega-3 fatty acids have a myriad of potential benefits for human health including reducing the risk of cardiovascular disease, improving brain growth and development, reducing inflammation in the body and reducing the risk of cancer –– just to name a few. Based on these potential benefits, it’s no wonder that the global market for Omega-3 products was valued at US$44 billion in 2020.

Solarvest BioEnergy (TSXV:SVS) is an innovative Canadian technology development company focused on producing a wide range of patented algae-derived products including Omega-3 supplements and therapeutic proteins. The company plans to deliver solutions in human and animal nutrition, prescription and non-prescription medication and derivatives through its proprietary clean energy algal production platform. Solarvest BioEnergy is led by a highly experienced management team with nuanced expertise and a proven track record of achievements in developing commercial biotech products.

solarvest Canadian technology development company

Technologies

Organic Omega: Solarvest BioEnergy’s algal production process allows for replicable, consistent and high-yield concentrations of final products for expedited product development and complex product versatility. It sustainably and efficiently produces organic certified Omega-3 fatty acids with five days of production resulting in tons of biomass. The company has produced the first and only FDA-approved DHA/EPA Organic Omega-3 supplement that is certified organic, vegan, allergen and pollution free, highly bioavailable, sustainable and non-GMO. Solarvest BioEnergy’s key consumer brand is called EverseaTM which brings the company’s first commercialized Organic Omega-3 products to market. The company’s Organic Omega-3 product(s) are plant based (from algae) so completely free of fish, unlike the majority of options in the market. The Organic Omega-3 product(s) is also available on the market white label.

Protein Expression: Solarvest BioEnergy has announced a successful proof of concept study for producing therapeutic proteins from algae. The first protein, bone morphogenetic protein (BMP6) is a highly valuable and complex protein that is used in human medicine to accelerate healing and enhance bone growth. Unlike current market options, the company’s BMP6 is safe as algae are free of any known human pathogens. The company is confident that it can produce other proteins. Solarvest BioEnergy will market its BMP6 and other potential proteins as approved pharmaceutical ingredients to large pharmaceutical companies.

The company has completed a feasibility study and implemented a research and development program to expand its product portfolio to include THC and CBD products. Solarvest BioEnergy believes that it can produce CBD from algae with its SVS algal expression platform. Compared to current CBD production methods, algal-based production will be significantly faster, higher quality, safer and since its produced in sterile bioreactors more controllable when compared to conventional agriculture.

H2 Expression: The company’s proprietary microalgae induction technology converts carbon dioxide and other nutrient waste streams into useful biomass and hydrogen

Solarvest BioEnergy has organized contract manufacturing for the commercial production of its Organic Omega-3 products. The company has secured an organic certified contract manufacturer from a German multi-billion dollar food company. Solarvest is also currently looking into the possibility of domestic production to build out the supply chain from its existing research and development facility in Prince Edward Island in Canada. The company also recently entered into a contract with Canada’s Smartest Kitchen to produce an ingredient blend for the plant-based seafood industry.

Solarvest BioEnergy has already filed 68 patents in commercially relevant markets including Europe, the US, Canada, Japan, China and Australia –– many of which have already been granted. In addition to Eversea’s e-commerce platform, the company plans to pursue a global penetration strategy by making strategic partnerships with organic food processors who to sell into large retailers and e commerce sites. This includes selling their Organic Omega-3 product as an additive or enhancement to organic food products such as dairy goods and smoothies sold by other companies. Given the importance of Omega-3 in brain development in babies and young children, the company will also market to the global infant and baby food segments.

Solarvest BioEnergy’s Company Highlights

Solarvest BioEnergy is an innovative Canadian technology development company focused on producing a wide range of patented algae-derived products for human and animal nutrition, prescription and non-prescription medication and derivatives.
Solarvest BioEnergy’s key consumer brand is called Eversea which brings the company’s first commercialized Organic Omega-3 product to market. The product is the first and only FDA-approved DHA/EPA Organic Omega-3 supplement that is certified organic, vegan, non-toxic, highly bioavailable, sustainable and non-GMO. It will be sold through strategic partnerships and white label selling.
The company’s proprietary clean microalgae process allows for expedited product development and versatility to produce multiple complex products.
Solarvest BioEnergy’s production technology successfully produced highly valuable and safe bone morphogenetic protein (BMP).
The company has a strong market growth strategy. The company plans to expand its product human therapeutic CBD and THC products.
Solarvest BioEnergy is led by a highly experienced management team with expertise and a proven track record of achievements in developing commercial biotech products.

Solarvest BioEnergy’s Key Products

Eversea

Eversea is Solarvest BioEnergy’s consumer brand of products. Eversea has brought the company’s Organic Omega-3 supplement to market through its e-commerce platform on its website. The product features a unique and patented Nanuq Organic Omega-3 ingredient which is certified organic in the European Union and by the USDA.

The Omega-3 supplement comes in the form of a dried fruit gummy that includes the companies patented long-chain Omega-3 which is significantly more bioavailable than current plant organic Omega-3 options which are short-chain. Known as ALA, (from Flax chia hemp) and only allow for less than 10 percent bio-absorption.

It is also pure with no solvents or chemicals such as hexane and acetone that are often used to extract Omega-3 oil from fish and krill. The Omega-3 supplement is also free of toxins and heavy metals such as mercury, PCBs and dioxins that are found in fish from the ocean. It is also completely free of fish and derived from algae which eliminate the risk of ocean-based contamination and saves dwindling native fish populations.

Eversea will bring to market various products that the company plans to release. Algae powder products will come in the forms of a processed food supplement, human nutraceutical, infant and baby food and a children’s supplement. Algae oil and beverage supplementation products will be human nutraceuticals. Pharmaceutical-grade oil will come in the form of an active ingredient and a carrier for bioactive products.

Solarvest BioEnergy’s Management Team

Gerri Greenham — CEO and Director

Gerri Greenham has been active in the biotech industry since 1983. He organized the acquisition from Connaught Laboratories of their biotech division to create Cobequid Life Sciences Inc. (TSE: KQR) that was subsequently acquired by Novartis Animal Health Inc. (“Novartis”) in 2000. Since then, he has been involved in private investments as well as sitting on boards of directors and advisory boards of various public and private companies.

Dr. Azoy Kumar Kundu — Senior Research Scientist

Azoy Kumar Kundu obtained his bachelor’s degree in Agriculture from Bangladesh Agricultural University. He completed his M.S. and Ph.D. degrees from Japanese universities on plant viruses and carried out his postdoctoral research at JIRCAS in Japan. Before joining Eversea Inc., Kundu served at AquaBounty Canada Inc. as a senior research scientist. Kundu developed PCR-based diagnostic assays to differentiate the genetically modified Atlantic salmon (GMO salmon) from the wild-type Atlantic salmon and validated several important studies for AquaBounty. Kundu has completed “Good Laboratory Practice Study Director/Principal Investigator Training” from the Society of Quality Assurance in the United States. Kundu has experience in molecular biology, cell biology, protein chemistry-based research works, a wide range of laboratory techniques and analytical instrumentation. Experience in these fields enables him to perform high-value protein expression studies in microalgae.

Garth Greenham — COO

Garth Greenham has an extensive record with both privately-held and publicly traded healthcare companies. He served as president of the global aquaculture division at Novartis Inc. He started his career with Johnson & Johnson (J&J) where he served 15 years mostly with McNeil Pharmaceutical in numerous management positions in operations. He joined Cobequid Life Sciences Inc. (KQR) and served as director of sales and marketing and operations for nine years. Greenham helped grow Cobequid Life Sciences to become a global leader in the field of aquaculture animal vaccines.

Dr. Michael Thomas Horne BA Ph.D. FRSB FCIM FIBMS CBiol CSci CMgt — Head of Research

Dr. Michael Horne is a Fellow of Royal Society of Biology (UK), Fellow of Institute Biomedical Scientists and a Fellow of the Chartered Institute of Management is Solarvest’s Head of Research. Horne obtained a first degree and Ph.D. in genetics at the Universities of Oxford and Wales (UCNW). He later taught genetics at UCNW and then at Stirling University where he was the head of genetics and director of the aquatic vaccine unit. He joined the Canadian company Cobequid Life Sciences Inc. (KQR) as a director of research, developing over 40 licensed products for aquaculture for 20 years. On the acquisition of KQR by Novartis, he remained the director of research and development. Throughout this period, he held a number of non-executive positions and directorships in companies. He also acted on the advisory panel of the Scottish Development Agency and worked with various UK national scientific committees and The Irish Board of Medicines. Before moving into the industry, he was the author of 65 peer-reviewed publications and many more articles, presentations and contributions to general journals. He is also an author and co-author of a number of issued patents.

Keep reading... Show less

Boosh Plant-Based Brands

Comfort Food Across Growing Markets in North America

Overview

Analysts project the plant-based meat market has the potential to grow by US$7.21 billion by 2025, with the market’s growth potential to accelerate at a CAGR of 25.14 percent. Consumers and national governing bodies have seen the appeal of more sustainable, plant-based meat alternatives as a long-term food production solution. Put in your source for the above stats

Canada, a global leader in plant protein, has invested over C$950 million in its SuperCluster initiative, with Protein Industries Canada standing as one of five sector recipients of that investment. With rapid popularity in plant-based food alternatives, investors could see exceptional early economic upside in these emerging markets across North America and the rest of the world.

Boosh Plant-Based Brands ((CSE:VEGI, OTCQB:VGGIF, FSE: 77I) is a plant-based ready-to-eat food company that distributes and sells plant-based fresh-frozen meals to grocery outlets and independent grocery stores throughout Canada. Founded in 2017 in Vancouver, British Columbia, the company aims to become a leader in delivering plant-based meals, which are sustainably packaged, convenient and tasty for complete customer satisfaction.

Boosh offers an award-winning product line featuring six fresh-frozen “Heat’n Eat” meals, including entrees for one, two and “Booch Pouches,” which are easy-warmed and hearty stews and sauces.

Boosh also provides a fuller range of competitive perks compared to other plant-based competitors. All Boosh meals are 100 percent plant-based, gluten-free, dairy-free and non-GMO. Likewise, the Canadian-based company offers complete composed dishes and two different meal sizes to satisfy individual and family dining wants.

The company has a highly strategic branding supply alliance with Beyond Meat®, one of the leading plant-based meat companies on the market. Numerous benefits have developed from this relationship including utilizing Beyond Meat® in two of Boosh’s dishs, as well as allowing Boosh to market both companies on Boosh packages, which significantly expands brand awareness for both notable companies.

In late 2020, UNFI, one of the largest natural food distributors in North America, began expanding Boosh distribution throughout Canada to over 300 locations and growing. Consumers can find Boosh meals in their local grocery and big box stores like Whole Foods Market, Metro, IGA, Safeway, SPUD.ca and more. With a strong in-store and online presence, Boosh gains exposure across multiple demographics at competitive price points.

The next steps for the company include the exciting launch of Boosh Pouches across grocery outlets in the Summer of 2021, which would introduce new offerings like Sloppy Joes, Mushroom Gravy and Chili. Also, Boosh intends to prepare for its expansion into US markets and roll out a more comprehensive commercial strategy targeting lifestyle channels in the Fall.

Boosh entered into an Asset Purchase Agreement with Saltspring Harvest to acquire the assets comprising Saltspring Harvest’s business. Founded in 2016 by Chef Zoe Currelly, Saltspring Harvest was formed to prove a plant-basprotein-richrich alternatives to meat and dairy focused pâtés and spreads.

With its established 8,500 square foot multi-use facility, the company expects to create extensive promotional content and educational material on the benefits of plant-based lifestyles, which will aid its introduction to new markets.

The Boosh ecosystem is a highly curated chain containing avenues of sourcing, product development, creative direction, distribution and retail store commercialization. With leading executives and industry greats like Boosh’s president, director and founder, Connie Marples, the company is primed for exceptional growth potential and economic success across its expansion plans.

Boosh Plant-Based Brands’ Company Highlights

Boosh Plant-Based Brands Inc. is an emerging plant-based comfort food company. It offers accessible, convenient and delicious “Heat’n Eat” fresh-frozen meals to a growing audience and plant-based meat market.
Boosh offers an award-winning product line featuring six delicious meals, including Boosh Bowls for One, Boosh Bowls for Two and Boosh Pouches, which will be introduced in Summer 2021.
All Boosh meals are 100% plant-based, non-GMO, gluten-free, dairy-free and offer sustainable packaging for its consumers.
The company has established itself as a major plant-based competitor on the market with its strategic branding and supply alliance with Beyond Meat
Boosh packages are available across over 300 grocery stores Canada-wide through UNFI
The next steps for the company include expansion into US markets and creating a more comprehensive commercial strategy to aid its introduction into new markets.
Boosh’s entire line of frozen ‘Heat n Eat’ bowls and entrees are now available at all Whole Foods Market locations across Canada.
Boosh completed its acquisition of Pulse Kitchen Specialty Foods Ltd.

Plant-Based Brands’ Key Products

Boosh Bowls

Its “Boosh Bowls for One,” offers a delicious range of meals across a wide set of cuisines like Veggie Bolognese, Mac & Cheeze & Peas, Coconut Curry Cauli, Mexican Fiesta. Additionally, its line of entrees for two offer bigger portions of crowd favorites like Rustic Veggie Pot Pit and award winning Hearty Sheperd’s Pie.

These 100 percent plant-based products contain no dairy, gluten, artificial colors and flavors and are non-GMO. Aimed to attract a wide audience of potential consumers, Boosh Bowls offer competitive pricing, sustainable and fully recyclable packaging and an exceptional plant-based alternative to crowd-favorites.

Boosh Pouches

Boosh’s newest plant-based offering is its Boosh Pouches which are a uniquely delicious line of three “Heat’n Eat” dishes, which include Chili, Mushroom Good Gravy and Sloppy Joe. The company is to begin production on July 30th, 2021 and the products will be distributed in Canada through UNFI.

Plant-Based Brands’ Management Team

Connie Marples – Founder, Director & President

Connie Marples is a seasoned executive and entrepreneur with an emphasis on the food and beverage industry. She has held several senior management positions in sales, promotions, marketing and fine dining. In 2003, Marples opened Vintropolis, a Vancouver-based wine bar and bistro/VQA Wine Store and in 2005 Vintropolis received the coveted position of being on the list of Condé Nast Traveller’s Best New Restaurants in the World. She also launched Okanagan Experience, an Entertainment style fundraising coupon book in Kelowna which was later sold to “Entertainment Book”.

As a sales representative, Marples helped launch New York Seltzer, oversaw corporate travel accounts such as the Vancouver Canucks, as well as managed grocery vendor programs and promotional departments at numerous large grocery retailers and radio stations. In the fall of 2020, She won the 2020 BC Food & Beverage Rising Star Award for her development and expansion of Boosh Food. She has expanded Boosh Food into a nationally recognized plant-food brand in Canada where Boosh can be found in over 150 major food retail stores and independent grocers.

Jim Pakulis – Director, CEO & Chairman

Ali is a seasoned executive with over 25 years of experience in food processing operations. He has a proven track record of expanding organizations, developing opportunities, and delivering goal-oriented results. His expertise in the food industry includes plant-based products, beverage, dairy, cereals, and snacks. Ali holds a bachelor’s degree in food technology and MBA in managerial leadership. He is currently the president of Wiseop Business Partners (a Vancouver based leading consulting firm in food processing operations), advisor to Plenty & Grace Food Hub, and Senior Advisor to Boosh Plant-Based Brands, Inc.

Ali Samei – VP Operations / Consultant

Jim Pakulis has over three decades of experience working with public and private entrepreneurial companies in a variety of emerging sectors. He is the former founder, CEO and chairman of TransCanna Holdings Inc., which through his initiative and execution acquired one of the largest vertically integrated cannabis-focused facilities in California. Pakulis has been in senior management positions for numerous publicly traded entities including CEO and chairman of General Cannabis, Inc. which from 2010 to 2012 wholly-owned Weedmaps. He oversaw the growth of General Cannabis from zero to over CAD$16-million in annual revenue.

Maria Hussaini – CPA, Director & CFO

Maria is a Chartered Professional Accountant with sound financial reporting, assurance and tax experience obtained from various roles in public accounting firms. In addition to being CFO of Boosh, she is a financial reporting manager at an accounting advisory practice where she works closely with various publicly traded companies in several industries.

Dave Richardson – Special Advisor

Mr. Richardson has an extensive background assisting emerging growth companies in numerous industries including the plant-based food sector. Mr. Richardson has experience as an investor, executive and founder of multiple technology companies. He is a proponent and defender for sustainability as well as the environment and is an Advisory Board member to several innovative green technology companies, as well as serving as a Director for GreenPower Motor Company.

Keep reading... Show less

Levitee Labs

Transforming the Traditional Landscape of Mental Health, Addiction Treatment and Pain Management Treatment Across Multiple Verticals

Overview

Shifting legal frameworks and regulatory changes have made psychedelic medicine one of the most promising solutions to mental health and addiction treatment in the modern age. Strong demand from therapists and patients for treatments involving psychedelic drugs like psilocybin has pushed the market to new heights, including a projected market size of over US$10.75 billion by 2027.

Globally, the market for functional mushrooms was US$5.8 billion in 2018 and could grow to a CAGR of 8.0 percent by 2024. Early-movers in the space can expect exceptional growth and economic success as the psychedelic space continues to gain traction as an increasingly positive remedy to limited responses to mental health, substance use and chronic pain crises around the world.

Levitee Labs (CSE:LVT,OTCPK:LVTTF) is an emerging leader in the integrative wellness space. The company will be the world's first psychedelic company with significant revenue and cash flow by year end 2021. Levitee Labs revealed that its M&A team has been tremendously successful in structuring transactions that will define the future of the company. Its acquisition pipeline is deep with a focus on pain & addiction clinics, specialized pharmacies, regulated telehealth, therapeutic psychedelic compound accessibility, and novel nutraceuticals.

Levitee Labs has established a profitable platform of integrative wellness assets through internal development and a regimented acquisition strategy. It operates a robust portfolio of revenue streams, including platform acquisition verticals of addiction and pain clinics, pharmacies and supplement & nutraceutical brands. The company also operates its divisional Sporeo Supply, which offers the gold standard of picks & shovels for mushroom cultivation.

Levitee's acquisition strategy includes a focus on addiction clinics & pharmacies. Recent acquisition ACT Medical Centres serves as a base for future clinic acquisitions and already has a patient base of 35,000 visits yearly, positioning Levitee as the largest non-government provider of addiction services in Alberta with 70% percent currently conducted via telemedicine. It provides Levitee with a platform for future research opportunities and allows for the future delivery of psychedelic medicine to addiction and chronic pain patients. The LTM revenue of this vertical is approximately C$7.5 million.

Additionally, Levitee's nutraceutical rollup and strategy are focused on a significant acquisition pipeline with over $50 million in revenue, which includes Earth Circle Organics. This acquisition already involved an executed LOI with an omni channel superfoods brand.

The company's Project Outback seeks to acquire a late stage applicant for a Health Canada sanctioned Controlled Drugs and Substances Dealer's License. This would allow Levitee Labs access to compounds such as psilocybin, MDMA, ketamine, LSD and DMT. The provisions surrounding the application would involve possession, production of base materials, delivery and import/export, which would widely expand the company's mission of traditional mental health and addictions treatment disruption and overall integrative wellness verticals.

Levitee Labs anticipates C$22.8 million in revenue in 2021. About C$13.2 million of the projected revenue comes from the company's ACT Medical Centres composed of five addiction clinics and three pharmacies. Levitee's major distribution partnership with My Green Planet is expected to have a year-end run-rate revenue of C$6 million while it expects C$3 million or 300% growth for its Earth Circle Organics acquisition.

The next steps for Levitee Labs include a psychedelic blueprint, which outlines an increased integration of alternative medicines and psychedelic therapies across its wellness platforms as regulations and shifting legal frameworks develop. Additionally, the company's R&D strategy is progressing sustainably, focusing on a rollout of alternative medicines to underserved patients.

The Levitee Labs management team comprises a diverse and complementary group of professionals across related fields in clinical research, public venture capital, M&A and operations. Together, they prime the company for exceptional growth potential, established key partnerships and positive financial valuations.

Levitee Labs' Company Highlights

Levitee Labs is a multidisciplinary company dedicated to redefining traditional mental health and addiction treatments through integrating evidence-based complementary medicines and novel psychedelic therapies into the traditional infrastructure of mental health treatment
The company's current major assets include addiction clinics, specialized pharmacies, a proprietary addiction-focused platform, an omnichannel nutraceuticals company as well as having internally developed a mushroom feedstock manufacturing facility
The company acquires and operates healthcare and nutraceutical assets through a vertically integrated M&A model, leveraging medical expertise, technology and resources
The company's nutraceutical and superfoods acquisition pipeline could bring over $50 million in revenue through Earth Circle Organics and others
Its Sporeo Supply mushroom cultivation asset offers exceptional internally developed picks & shovels and involves a major distribution partnership with My Green Planet.
Its Superfoods and Nutraceuticals vertical involves brands like Earth Circle Organics, OJIO, Earth Shift Products, Project Buddha and MONKE Nutraceuticals.
Levitee Labs has a market cap of approximately C$37.5 million, an enterprise value of C$26 million, and a tight capital structure.
Levitee Labs completed the acquisition of BlockMD Telemedicine Platform, three specialised pharmacies and five addiction clinics in Alberta.
The company's management team is a strategically diverse and robust group of professionals with experience across an array of related fields including psychedelics, clinical research and strategic alliance.
Levitee Labs added superfoods to its portfolio by completing the acquisition of all the issued and outstanding shares of Earth Circle Organics Chain Inc.

Levitee Labs' Integrated Wellness Portfolio

Clinic and Pharmacy Acquisition Strategy

Levitee's acquisition strategy focused on addiction clinics, pharmacies and pain management clinics serves as a platform for addressing the burden of inefficiencies prevalent within current clinical treatments, particularly those available to underserved patient populations. Levitee has acquired five clinics, three specialized pharmacies and a telemedicine platform, which the company intends to add additional services to treat underserved patients through innovative digital drug delivery avenues as the market expands.

The ACT Medical Centres acquisition has an estimated enterprise value hovering around C$5.9 million with a C$7.5 million LTM revenue and C$1.1 million EBITDA. The roll-up strategy would also include research into psychedelic medicine and trials of novel psychedelic compounds.

Nutraceutical Acquisition Rollup

Levitee's division of nutraceutical strategy focuses on acquiring brands that are established but lack an e-commerce presence with little to no marketing expenditure. These brands offer the company a first-mover advantage with early-stage positioning in growth, high search volume and limited established competitors. These companies also have proprietary products with exceptional economic volume but high barriers to entry. Levitee's main brands include MONKE Nutraceuticals and executed LOI involving Project Buddha and Earth Circle Organics.

MONKE Nutraceuticals is an internally developed, premium functional mushroom company, which offers expansive distribution opportunities across Levitee's larger acquisitions.
Earth Circle Organics is an omnichannel superfoods and supplements brand with a 300 percent growth rate in the last two years and contains over 180 SKUs across three encompassed brands.

Sporeo Supply – Mushroom Cultivation

Sporeo Supply centralizes all sterilization operations and offers cultivators high yield growth formulas for mushroom spawn and substrate. The company is currently building a production facility near Vancouver, British Columbia that will address the market fragmentation for mushroom cultivators, increase standardization of manufacturing practices for future psilocybin production and advance its production of ready-to-grow mushroom kits for consumers.

Its products will be available through retail, wholesale and e-commerce channels and aim to defragment the mushroom cultivation ecosystem. The company has secured a strategic partnership with My Green Planet to expand its reach and provide cultivators with the full range of growing materials required for the cultivation of all mushrooms.

Levitee Labs' Management Team

Pouya Farmand – CEO & Co-Founder

Pouya Farmand is an experienced financier and entrepreneur with over ten years in the financial markets, primarily in investment banking and venture capital. He has been involved in over 35 transactions ranging from C$1 million to C$50 million.

Kelly Abbott – COO & Director

Kelly Abbott has over ten years of experience in entrepreneurship and software development. He was the former founder and CEO of ParcelPal Technologies, overseeing over 400 employees at its peak.

Mason M. Darabi – CFO

Mason M. Darabi is an experienced CPA with a long history of working in various accounting roles in Canadian accounting firms including MNP, Imperial Oil, RSM Canada and PwC. In his most recent role, he led Ag Data from an idea to a thriving initiative, at the national level for MNP LLP.

Ken Osborne – CFA, Head of M&A, Co-Founder

Ken Osborne is a capital markets professional with diverse experience in both public and private markets covering over 20 capital raises and C$500 million in M&A activity.

Dr. Mohammed Mosli – Chief People Officer (Levitee Clinics, Alberta)

Dr. Mosli is a multilingual Public Health and Preventive Medicine physician specialized in Addictions Health, health services improvement, health promotion, environmental public health, and health policy. Throughout his career, Dr. Mosli served, or currently serves as a director, educator, or senior level manager for an array of organizations, including those in provincial, institutional, and private segments. He is a valuable physician member of the Opioid Addictions Medicine team for Levitee Clinics™ and Levitee Pharmacies™ in Alberta.

Marc Momeni – Executive VP

Marc is a finance professional with over 10 years of experience in financial services and banking. With a key competency in building and managing teams, Marc has been able to scale multiple businesses from start-up to over 7 figures.

Fady Hannah-Shmouni – Chief Medical & Scientific Officer

Dr. Hannah-Shmouni was a clinician scientist in neuroendocrinology, hypertension, and biochemical genetics at NIH (Maryland, USA) since 2015. He served as Director of the Office of Education's Graduate Medical Education (GME) with the National Institute of Child Health and Human Development; Chief of the Internal Medicine, Endocrinology, and Genetics Inpatient Ward; Associate Program Director of NIH's Inter-Institutes Endocrinology & Metabolism Fellowship Program; and Principal Investigator of neuroendocrine genetic and hypertension disorders.

Dr. Hannah-Shmouni specializes in neurohormonal dysregulation of the stress system, with a clinical focus on studying the effects of psychedelic therapies on endocrine conditions and different hormone axes. This specialization in stress hormones uniquely positions Dr. Hannah-Shmouni to provide clinical insights on the prolonged effects of stress that can lead to mental health disorders.

Azim Qazi – Head of Ecommerce and Consumer Packaged Goods

Azim Qazi has over 20 years of experience with broad expertise in dynamic retail marketplaces, business development and supply chain management to oversee Company-wide CPG operations, beginning with the recently launched product lineups of MONKE Nutraceuticals, and Earth Circle Organics. Prior to Levitee Labs,he has worked with Cymax Stores and Cymax Group in multiple leadership positions including Category Manager at Cymax Stores during which he developed objectives and key results for key categories representing 50 percent of total revenue, managed 32 separate $1 million vendors, negotiated marketing promotions, analyzed PPC campaigns and grew category revenue by 39 percent.

Noha ElSayed - Executive Director Levitee Clinics & Levitee Pharmacies, Alberta Region

Mrs. ElSayed brings a wealth of expertise gained through a variety of clinical and managerial positions held in retail pharmacies, hospitals, and primary care settings while working as a pharmacist for the last 20 years, including 11 years as a pharmacy manager. Mrs. ElSayed earned her Bachelor of Science degree in Pharmacy and obtained her Additional Prescribing Authorities from The Alberta College of Pharmacists. She is an active member of several specialized health care networks as the International Society of Travel Medicine and The Canadian Obesity Network. Mrs. ElSayed has a passion for mental health care, addiction treatment, custom compounding, and travel health, as well as diabetes and chronic disease management education. She prides herself on staying up-to-date with the latest pharmacy practices and procedures and is an expert in custom compounding techniques and knowledge.

Keep reading... Show less

Avricore Health

Avricore Health: Empowering Patients with Rapid Testing in Community Pharmacies

Overview

In 2020, the global point-of-care testing (POCT) market was valued at US 34.49 Billion and expected to expand at an annual growth rate (CAGR) of 9.4 percent to reach a projected US 81.37 Billion by 2028. The upsurge will be driven largely by increased demand for screening and managing chronic diseases as well as rapidly assessing infectious diseases such as COVID-19.

The accessibility of POCT has been an increasing priority of the world’s leading health organizations and experts. Pharmacies are ideal ‘hubs’ within the community to offer patients better access to the numbers they need to know for preventing or treating conditions such as diabetes and heart disease or the timely diagnosis of infection.

Avricore Health Inc. (TSXV:AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering HealthTab™ (a wholly owned subsidiary), its mission is to make actionable health information more accessible to everyone by creating the world’s largest network of rapid testing devices in community pharmacies.

HealthTab™ is a turnkey point-of-care testing solution that effectively turns pharmacies

into diagnostic hubs (sometimes known as ‘Community Diagnostic Centres’ or CDCs) and connects them on a single, cloud-based platform.

The HealthTab™ network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery, while empowering patients to take more control of their health. It also reduces costs and waiting times and provides many potential revenue streams including: equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets, and third party app integration through API.In June 2021, Avricore signed a Master Agreement with select Shoppers Drug Mart pharmacies to pilot the HealthTab™ platform. This agreement allows patients access to point-of-care blood screening and health-data management for potential risks for developing diabetes and cardiovascular conditions through the HealthTab™-integrated Afinion 2™ analyzers by Abbott Rapid Diagnostics.

Avricore is the first pharmacy solutions provider to partner with Abbott (NYSE:ABT), the global healthcare company and diagnostics leader in Canada. In May 2021, it signed a supplier distribution agreement to expand the distribution of Abbott’s Afinion 2™ and associated tests for diabetes and heart disease screening in community pharmacies in Canada. This agreement includes valuable HbA1c testing, a critical marker for the screening and management of diabetes.

Near term goals for the company include expansion into more pharmacies across Canada, followed soon after by entering the US and UK markets. It has made significant strides in testing and developing its technology and is moving into the commercialization stage.

Strategic partnerships like Abbott and pharmacy-focused pilot opportunities advance Avricore closer to becoming an incredibly dominant player in the community diagnostics space. The company aims to make actionable health information more accessible for everyone by creating the world’s largest rapid testing network in pharmacy.

Avricore Health’s Company Highlights

Avricore Health Inc is a pharmacy solutions provider that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues
The wholly owned subsidiary, HealthTab™, offers fast, accurate and cost effective point-of-care screening. With just a few drops of blood from a finger prick, results are available on the spot and data is available in real time
The current test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g. HbA1c, Lipid Profile, eGFR). HealthTab™ has also recently added capabilities for bacterial and viral tests, such as strep and COVID-19
The company leverages strategic partnerships with notable names in the diagnostic space, including Abbott Rapid Diagnostics, a global healthcare company and leader in diagnostics. This partnership allows Avricore to use Abbott’s Afinion 2™ analyzer to offer high quality, low-cost screening tests
In June 2021, Avricore announced its Master Agreement to pilot its HealthTab ™ platform for diabetes management in select Shoppers Drug Mart pharmacies
Avricore’s ultimate aim is to make actionable health information more accessible to everyone by creating the world’s largest network of rapid testing devices in community pharmacy
The company expanded patient testing with the HealthTab™ platform in select Shoppers Drug Mart® pharmacies in British Columbia, bringing its diabetes screening program to Western Canada for the first time.

Avricore Health’s Management Team

Avricore’s leadership team brings a diverse portfolio of expertise across healthcare and biotech industries as well as technology, finance and communications. Together, they share a common vision for moving pharmacy forward and have positioned the company for significant future growth and expansion.

Hector Bremner – CEO

Hector Bremner has over fifteen years of senior and executive experience across various industries, including international trade, natural gas, marketing and communications. He has owned and operated TOUCH Marketing, a boutique marketing and communication firm based in Vancouver, from 2007 to 2013.

Bremner has also served as the executive assistant to the Deputy Premier and Minister of Natural Gas Development, Responsible for Housing, as well as the Minister of International Trade and Minister of Small Business. In 2015, he joined Vancouver’s Pace Group Communications as VP of Public Affairs.

David Hall – Chairman and Director

David Hall’s leadership spans five different companies. Aside from acting as Chairman and Director at Avricore, he is also currently the Chairman of RepliCel Life Sciences, a member of the board of TrichoScience Innovations, AdvantageBC and Providence Health Care Research Institute.

Hall also served as Chairman of Perceptronix Medical, Inc., Chief Financial Officer, Secretary & Treasurer of Angiotech Pharmaceuticals, Inc., President & Director at Newcastle Resources Ltd. and Chairman for LifeSciences British Columbia.

Kiki Smith – CFO

Kiki Smith has over 20 years of experience assisting private and public companies in the roles of accountant, corporate controller and CFO in mining, oil & gas, real estate, high technology, food production and investment fund management. She currently provides consulting services in M&A, financial reporting and regulatory compliance to several public and private companies across several investment sectors.

Smith is also a member of the Chartered Professional Accountants of British Columbia. She has a Bachelor’s degree in Economics from the University of British Columbia.

Rodger Seccombe – Head of HealthTab™ Division

Rodger Seccombe is the co-founder and former CEO of HealthTab™ Inc. He has over 20 years of experience launching and running companies in software, healthcare technology and clean energy. Seccombe is a recognized industry expert in direct-to-consumer and point-of-care testing technology.

In 2006, he joined the start-up team at Canadian Bioenergy Corporation and helped pioneer the development of the renewable fuel industry in Canada. Before HealthTab™, he designed and developed cloud-based informatics systems currently in use by some of the world’s leading medical laboratories and instrument manufacturers.

Keep reading... Show less

Avisa Diagnostics

Developing A Thermometer for the Lungs

Overview

The global healthcare industry continues to experience rapid growth. With an average annual growth rate of 7.3 percent since 2014, healthcare spending is expected to exceed $10 trillion by 2022. Healthcare spending in the US accounted for 17.7 percent of the entire GDP in 2019, with that figure expected to rise to nearly 20percent by 2028.

Segmentation is an important consideration when it comes to investing in healthcare companies. Respiratory diagnostics is one segment within the healthcare industry to keep on the watchlist, especially in the wake of the COVID-19 pandemic. Before COVID-19, a child dies of pneumonia every 39 seconds and the United Nations Children’s Fund (UNICEF) projected around 18 million more health workers are needed by 2030. Amid the pandemic, pneumonia and other respiratory diseases become an even larger health concern. The respiratory disease diagnostics market alone is expected to be worth $6.7 billion by 2025.

Avisa Diagnostics (CSE:AVBT) is an innovative healthcare company specializing in respiratory disease diagnostics through its rapid, point-of-care Avisa BreathTest solution™. This simple, ultra-rapid breath test was designed to save time, money and lives, and has been dubbed a “thermometer for the lungs.”

The compelling new technology measures bacterial load in the lungs enabling better diagnoses, monitor therapy, and helping to mitigate the overuse of broad-spectrum antibiotics.

UN reports show that bacterial resistance is responsible for over 700,000 deaths worldwide and millions in healthcare costs. More targeted technologies, like the Avisa breath test, allow for specific diagnosis and prevent the unnecessary use of broad-spectrum antibiotics.

The technology also aids doctors in monitoring patients on ventilators. An estimated 1.7 million people are on ventilators in the US alone, and nearly half of all individuals on a ventilator get ventilator-associated pneumonia which can potentially be fatal. The Avisa breath test allows for unprecedented monitoring and has the potential to save thousands of lives.

In terms of early detection and the ability to allow physicians to rule in or out specific diagnoses, there is no comparable technology on the market today. Avisa BreathTest™ has the ability to quickly detect urease pathogens anywhere in the lung within 10 minutes, with AVISAR™, a point-of-care medical device that provides analysis in seconds.

Avisa is currently in the process of putting together their investigational new device exemption for the FDA. Pending approval, they will then be able to move into commercialization.

Any new technology is only as profitable as the team managing its release, and Avisa has put together a team with proven experience in key areas of diagnostics, clinical regulation and strategy, medical device design, as well as medical technology. This positions them well in the testing and commercialization of new medical technology.

As the Avisa breath test approaches clinical trials, it will be essential to have leaders experienced in developing strategic research trial operations and gathering the necessary evidence to take the device to market.

CEO David Joseph has over 40 years of experience in the commercialization of medtech and pharmaceuticals, co-founding four companies in the industry, which were successfully exited through IPOs and M&As.

VP of Clinical Development Barbara Bunger, Ph.D. has over 30 years of experience navigating clinical trials. He currently serves as the vice president at Clinical Development and Regulatory Services, LTD, a company providing scientific, clinical research and regulatory services to the biopharmaceutical and medical device industry.

Avisa Diagnostics’ Company Highlights

Avisa Diagnostics is a clinical-stage medical device company developing the Avisa BreathTest™, a novel drug/device biomarker technology platform that enables the ultra-rapid detection of virulent bacterial pathogens, detecting and monitoring bacterial load after the patient inhales or ingests its drug substrates via proprietary delivery systems.
The respiratory disease diagnostics market alone is expected to be worth $6.7 billion by 2025, and the Avisa BreathTest™ is a unique technology addressing a prevalent issue within this growing market.
1.7 million people are on ventilators in the US alone, and nearly half of all individuals on a ventilator get ventilator-associated pneumonia, a potentially fatal condition. The Avisa breath test allows for unprecedented monitoring and has the potential to save thousands of lives.
Avisa is currently in the process of putting together their investigational new device exemption for the FDA. Pending approval, they will then be able to move into commercialization.
Avisa’s management team has decades of combined experience in the development and commercialization of medical technology, diagnostics and clinical regulation and strategy. Experience in these key industries put them in a strong position to move the Avisa BreathTest™ through clinical trials and into commercialization.

Avisa Diagnostics’ Breakthrough Technology

Avisa BreathTest™

The Avisa BreathTest™ is a novel drug/device biomarker technology platform that enables the ultra-rapid detection of virulent bacterial pathogens. It works by detecting and monitoring bacterial load after the patient inhales or ingests its drug substrates via proprietary delivery systems.

Avisa has established clinical proof-of-concept through trials in cystic fibrosis, tuberculosis and community-acquired pneumonia, which demonstrated positive safety and clinical efficacy results.

Pivotal trials are also planned in Post-COVID-19 bronchiectasis and ventilator-associated pneumonia and plans to submit Investigational Device Exemption applications to the U.S. FDA for these trials next year.

The breath test is a novel use of existing technology with a clinical proof-of-concept, which mitigates the risk when moving through clinical trials.

Avisa has sufficient funding to reach key value inflection points through product launch, as well as a smart business model developed by experienced leaders which will enable accelerated market entry.

Avisa Diagnostics’ Management Team

David S. Joseph — President & CEO

David S. Joseph has over 40 years of experience commercializing medtech/pharma, including co-founding four companies with successful exits either through IPOs or M&As.

Joseph was the Co‐founder, President, CEO and Chairman of SITE Microsurgical Systems, which was acquired by Johnson & Johnson Corporation (NYSE:JNJ) in 1983. He was also co-founder, President, CEO and Chairman of Surgical Laser Technologies, which reached IPO in 1989 and was acquired by Photo Medix in 1992.

Joseph then moved on to Orthovita, an orthobiologics company which reached IPO in 2006 and was acquired by Stryker (NYSE:SYK) in 2012 for US $350 million.

Prior to his entrepreneurial career, Joseph accrued over 15 years of executive healthcare management experience.

David Karshmer — SVP, Product Development

David Karshmer has over 25 years of experience in medical device design, providing a solid foundation for heading up the design of Avisa’s new breath test device.

Karshmer is also a successful serial entrepreneur, Avisa being his 6th start-up. He also founded IDEO Healthcare practice.

G. Michael Landis — CFO

G. Michael Landis has over 25 years of finance and accounting experience in a variety of industries and has strong public company expertise, including the areas of capital market transactions, investor relations and financial reporting.

Prior to joining Avisa, Mr. Landis served at Lannett Company, Inc., a publicly traded generic pharmaceutical company, in various financial leadership roles, most recently as Principal Accounting Officer and Treasurer. While there, he led acquisitions and related financing activities and was a member of the executive team that successfully completed a $1.2 billion acquisition.

Barbara Bunger, Ph.D. — VP, Clinical Development

Barbara Bunger has over 30 years of industry experience, boasting a highly successful track record in the development of clinical and regulatory strategy, global clinical research trial operations and the overall evidence generation planning required to support reimbursement and market adoption.

She is the Vice President of Clinical Development and Regulatory Services at Clinical Development and Regulatory Services, LTD., a company providing scientific, clinical research and regulatory services to the biopharmaceutical and medical device industry. She is also Worldwide Director for the Clinical Research and Corporate Clinical Development at Becton Dickinson.

Bunger has led clinical research and regulatory functions at several clinical and regulatory consulting firms as well as at medtech companies including Medtronic Spine & Biologics, SI-Bone, Philips Healthcare’s emerging business unit and Triangle Research and Regulatory Services.

Graham Timmins, Ph.D. — Chief Science Advisor

Graham Timmins, associate professor of medical chemistry at the University of New Mexico, is the chief scientific advisor on the Avisa BreathTest™ project.

Timmins is the author or co-author of over 50 scientific publications during the course of his academic career, and has been awarded multiple federal grants.

He is also the co-inventor of the Company’s patent portfolio.

Dr. Richard Murray — Chief Medical Officer

Dr. Murray has over 25 years of industry experience. He worked at Merck & Co. for many years in positions of increasing responsibility, in a variety of business, medical and scientific areas. His most recent position was Vice President and Deputy Chief Patient Officer. Dr. Murray was also a Fellow at the Advanced Leadership Initiative at Harvard University. He has managed all areas of medical affairs, including outcomes research, medical information, professional and academic affairs, field-based medical physicians, and investigator-initiated trials globally.

Keep reading... Show less

Cloud DX

Digitally Driven Solutions Through Integrated Medical Devices and Cloud-Based Software

Overview

The COVID-19 global pandemic shook traditional healthcare structures on a global scale in 2020. There has been an urgent need for integrated systems to manage the influx of patients and new social distancing measures, which forced many to delay seeking in-person medical attention. In identifying this gap in the healthcare system, digitally driven telemedicine companies are leading the way to innovate and improve healthcare for all in this increasingly digital age.

By 2022, the global healthcare market is forecasted to grow to US$11.9 trillion, with the digital healthcare sector to grow by a projected compound annual growth rate (CAGR) of 38 percent by 2026. In dealing with the aftermath of this pandemic, investing in healthcare and wellness technology is investing in the healthcare systems we’ve needed for a long time.

Cloud DX is a digital health company focused on providing sophisticated solutions for advanced healthcare providers through its precision vital sign monitoring platform, software and mobile apps. The company’s commitment is to the improved accessibility of healthcare through virtual care and digital medicine across Canada and the United States.

The company combines core competencies in biomedical hardware engineering, cloud-based medical device architecture, algorithm-based result generation, regulatory approval experience and internationally ISO certified quality management. This combination has helped Cloud DX develop optimized medical devices and software for a more value-added patient experience. This level of innovation in telehealth technology strategically positions Cloud DX as a leader in vital sign data monitoring and integration.

Unlike many other telemedicine companies, Cloud DX works to invent new medical devices and get them cleared by regulators. This invention aspect allows the company to create more intuitive and innovative devices at potentially lower costs for its users. “Because we control that entire customer experience, we can optimize it and make it better for everybody. That, in fact, is our mission,” Cloud DX CEO Robert Kaul stated.

Cloud DX has partnered with healthcare providers like the Blessing Health System and virtual care companies like Curatio Inc, co-creator of the Stronger Together app, to provide remote patient monitoring and telehealth solutions to COVID-19’s short term symptoms and its long term complications. This new wave of virtual care technology addresses limitations to existing healthcare structures and helps meets the demand for medical aid in light of strained traditional healthcare systems and broad social distancing measures throughout North America.

In August 2014, Team Cloud DX was confirmed as a top 10 finalist in the Qualcomm Tricorder XPRIZE out of 330 entrants. This three-year global competition offered a US$10 million prize purse to be distributed among the top 3 teams who could develop an autonomous vital sign data collection and remote diagnostic platform inspired by the famous medical “Tricorder” from the TV show Star Trek. Cloud DX’s entry, the VITALITI platform, was successful at diagnosing up to 19 separate health conditions, all by itself. The company, which was the only competitor representing Canada, received the first XPRIZE Bold Epic Innovator Award in April 2017. All the winning XPRIZE Teams share access to a multi-million dollar pool of grant funding provided by the Qualcomm Life Foundation and the Roddenberry Foundation to bring their inventions to market, administered by the University of California San Diego.

XPRIZE winning VITALITI Tricorder by Cloud DX

Cloud DX is commercializing three inventions based on their XPRIZE winning Tricorder. The Pulsewave 2.0 wrist cuff monitor can uniquely measure accurate blood pressure and average breathing rate simultaneously. The wearable VITALITI continuous vital sign monitor streams all the main vital signs including multi-lead ECG and non-invasive blood pressure to the cloud in real time, while their AcuScreen CA cough analysis smartphone application can detect respiratory disease based on the sound of a person coughing, and is in clinical trials to screen for tuberculosis, expected to be completed by 2022.

Immediate plans for the company include an intended public listing on the Toronto Venture Stock Exchange in early 2021 and the advancement of its innovation pipeline. Its strong patent portfolio strategically positions the company for significant investor potential and technological expansion.

Cloud DX’s management team combines years of experience in medical care, finance, risk management and web-based engineering. This dedicated team primes the company for significant telehealth advancement, product development and revenue growth.

Cloud DX’s Company Highlights

Cloud DX is a virtual care and digital medicine company focused on providing innovative medical solutions to healthcare providers and patients alike. The company is committed to meeting the demands of patients while addressing the limitations of traditional healthcare structures.
The company works to invent fully connected and cloud-based medical devices that monitor vitals and health data at competitive costs. Cloud DX works directly with doctors, healthcare providers, regulatory bodies and patients
Cloud DX has received over a dozen awards for innovation, including Bold Epic Innovator in the Qualcomm Tricorder XPRIZE, “World Changing Idea” from Fast Company and most recently, finalist in the 2021 Edison Awards.
Cloud DX is certified in Quality Management under ISO 13485, licensed to develop medical devices and software by Health Canada and registered (with 510k clearances) with the US FDA.

Cloud DX’s Key Products

Connected Health Kit

The Cloud DX Connected Health platform combines integrated telehealth monitoring software and high-tech medical hardware. Patients can record their vital signs, complete important surveys to answer questions from a personalized care team, access a curated health feed customized to their condition and have full control over their full patient history through the Cloud DX patient portal.

Cloud DX Connected Health Kit

Additionally, a typical Connected Health Kit comes equipped with a custom Android tablet, a Pulsewave wrist cuff blood pressure monitor, a wireless Bluetooth scale and a wireless pulse oximeter. Smart software in the privacy-compliant Microsoft Azure cloud detects changes to vital signs, survey answers or device use patterns and notifies caregivers so that immediate interventions can occur, improving health outcomes. This virtual care paradigm is an exciting innovation, aiming to answer the demands of a rapidly changing digital medicine landscape.

Pulsewave Wrist Cuff Health Monitor

The Cloud DX Pulsewave health monitor wrist cuff is a unique, connected medical device that allows users to immediately see their heart activity with clinical accuracy. The comfortable wrist cuff transmits the raw pulse wave signal to Cloud DX servers for analysis, producing heart rate, blood pressure, pulse variability, average breathing rate and a proprietary cardiac anomaly score.

“Total Anomaly Score is a novel screening tool that appears to have significant potential for identifying cardiac diseases. Possible clinical uses for this score are under active investigation at Cloud DX,” Chief Medical Officer Dr. Sonny Kohli noted.

The company expects to launch Pulsewave 2.0, a major upgrade to their original wrist cuff, in 2021. The new device is wireless, battery powered, with an on-board accelerometer and gyroscope, improving performance. Production of Pulsewave 2.0 is supported by a non-dilutive $1.75 million co-investment from the NextGen Manufacturing Supercluster.

Cloud DX’s Management Team

Robert Kaul – CEO, Founder & President

Robert Kaul has over 30 years of experience as an entrepreneur, and Cloud DX is his 6th startup. With a BSc in Biology and a certificate in Operations Strategy from MIT-Sloan, Kaul is recognized as an expert in creating and inspiring highly capable teams.

Dr. Sonny Kohli, MD – Co-founder & Chief Medical Officer

Dr. Sonny Kohli is an Attending Physician in Intensive Care and Internal Medicine at Oakville Trafalgar Memorial Hospital and an assistant clinical professor (Adjunct) of Medicine at McMaster University. In 2008/09, Dr. Kohli was an Astronaut Candidate at the Canadian Space Agency (CSA), where he was awarded a Scholarship to the Johnson Space Center.

Anthony Kaul – Co-founder & COO

Anthony Kaul is the founder & CEO of Higher Bracket Online Media, Canada’s only online resource for $100K careers. He has over 25 years of corporate leadership experience and is responsible for all day-to-day operations at Cloud DX including HR, Purchasing, Finance, Sales, Marketing, and much more.

Simon Selkrig – Chief Financial Officer

With more than 20 years of finance, accounting and strategic planning experience, Simon has worked in professional services, industrials, mining and resources, banking, and e-commerce sectors in Canada and internationally. In his new role, Simon will lead Cloud DX‘s finance department including finance, tax, capital, investor relations (IR) and strategic growth initiatives. Former CFO Stephanie Bird will continue to be available as an Executive Consultant. Simon joins Robert Kaul, CEO and Anthony Kaul, COO as a member of the Executive Team.

Nick Mulder – Head of Software

Nick Mulder has over 18 years of experience building web-based systems and over 12 years of experience building high-performance teams. Before joining Cloud DX, Mulder was the senior engineering lead that founded and grew the product and engineering team at Shopify Plus in Waterloo, growing the team from 4 to 400 in three years.

Sara Ross-Howe, BASc, MASc – Head of Research & Development

Sara Ross-Howe brings 16 years of experience developing advanced technology solutions for consumers. She started her career managing a team of scientists applying machine learning techniques to biomedical diagnostics. More recently, she spent over a decade managing a technology group creating audio and video recording solutions and cloud transcription for national court systems.

Keep reading... Show less

WellteQ Digital Health

Corporate Health and Wellness Through Mobile Applications and Virtual Healthcare

Overview

In 2020, the COVID-19 global pandemic shook traditional healthcare structures on a worldwide level. Not only did healthcare institutions need integrated systems to manage the influx of patients and personalized information, but companies needed to keep track of the wellness of their teams as large numbers of employees switched to remote work environments.

In this increasingly digital age, the sphere of telemedicine helped to not only revolutionize healthcare navigation but our perception of wellness management. Telemedicine has proven that the world could use innovative digital technologies to not only manage health complications but potentially proactively prevent them. As the global healthcare market is forecasted to grow to nearly US$11.9 trillion by 2022, investing in wellness technology today is investing in the healthcare of tomorrow.

WellteQ Digital Health (CSE:WTEQ) (OTCQB:WTEQF) is a digitally driven health and wellness company aiding the transition from old school healthcare navigation to a more personalized data-driven patient experience. Through data capture, artificial intelligence and analytics solutions, the company seeks to help people take control of their own wellness and overcome accessibility issues around health.

Keep reading... Show less

Leveljump Healthcare

Representing the Future of Diagnostic Imaging in Canada

Overview

Diagnostic imaging represents the cornerstone of modern healthcare, with availability and accuracy playing important roles in improving patient outcomes. However, access to cutting edge equipment, as well as a shortage of radiologists in small urban and rural hospitals across Canada, has led to a delay in the medical imaging process for patients that need it most.

By 2027, the global medical imaging market is expected to reach US$43.33 billion. One of the major movements within the Canadian healthcare industry involves establishing and maintaining a standard of consistent and efficient care across small, large, rural and urban hospitals. On average, nearly 30,000 patients require a CT scan every month in Ontario, suggesting an urgent need for teleradiology services that may decrease the delay for emergency room patients seeking immediate medical attention.

Leveljump Healthcare (TSXV:JUMP) (OTCQB: JMPHF), or JUMP, is a healthcare company that offers teleradiology solutions through its wholly owned subsidiary Canadian Teleradiology Services (CTS), which specializes in off-site readings of radiology scans on-demand, 24 hours a day and seven days a week. CTS has been active in the Canadian medical imaging sector since 2004 and provides reading services for a diverse range of medical imaging tests, including MRIs, CT scans, ultrasounds, X-rays and more.

Remote radiology was designed to overcome a shortage of radiologists and decrease wait times for emergency room patients. With this system, once a hospital conducts a radiology scan, scan results are immediately forwarded to CTS and analyzed by a team of qualified radiologists. All analyses are completed remotely using a secure server. Findings are then reported within 60 minutes in emergency cases and within 24 hours for elective work. On-site medical staff then rely on the findings to form an accurate diagnosis, informing subsequent treatment.

JUMP powers its remote teleradiology services by relying on multi-year contracts that offer automatic renewals, ensuring long-term partnerships with recurring revenue streams. By 2023, the company plans to increase CTS partnerships to a total of 112 Canadian hospitals, expanding across provinces and offering valuable services for private clinics that are severely understaffed. Over its 16 years of operation, CTS has demonstrated a strong financial performance, with existing positive cash flow coupled with 12-18 percent growth per year over each of the last three years.

The growing digital health market is transforming the delivery of healthcare to Canadian patients. JUMP is continually focused on new opportunities within the diagnostic imaging industry by investing in innovative, patented technology as well as securing the distribution rights for up-and-coming diagnostic imaging hardware. Similar teleradiology and telemedicine companies within the sector include HCA Healthcare (NYSE:HCA), MEDNAX (NYSE:MD) and Teladoc Health (NYSE:TDOC).

Healthcare is one of the few industries that is considered “recession-proof,” and diagnostic imaging represents one its core pillars. JUMP is now focused on targeting its remote radiology services toward independent health facilities (IHFs) with long-term plans of building a national chain of diagnostic imaging clinics. The company’s imaging center acquisition strategy is focused on consolidating a segmented industry that currently operates without a large regional presence. The company plans to establish a brand that referring physicians can depend on and that represents the very best of patient care.

Leveljump Healthcare’s Company Highlights

LevelJump Healthcare is a healthcare company that offers teleradiology solutions through its wholly owned subsidiary Canadian Teleradiology Services (CTS).
CTS provides 24/7 remote radiology services that offer a significant benefit toward severely understaffed hospitals and private clinics across the country.
The company has shown organic growth from existing contracts.
JUMP is focused on the acquisitions of private clinics (IHFs) with the long-term goal of establishing a dominant national provider of imaging services.
LevelJump has closed its acquisition of 23.8 percent of the issued and outstanding shares of each of Shaw Vision Inc. and Shaw Lens Inc.

Canadian Teleradiology Services (CTS)

Diagnostic imaging represents a core pillar of Canada’s healthcare system, especially when faced with the country’s aging population. However, the demand for radiologists is increasing at a faster pace than the workforce is growing. Remote radiology represents one of the easiest ways for hospitals to keep their emergency departments well-prepared at all times.

JUMP owns and operates CTS, which specializes in offering 24/7 on-call remote radiology services. Over the past 16 years, CTS has established itself as a leader in emergency room radiology services.

Innovative Technology

CTS relies on a secure server and specialized software to transmit diagnostic images to a team of board-certified radiologists. The platform relies on technologies such as advanced graphics processing, voice recognition and image compression to support a prompt and accurate analysis.

Specialized Staff

CTS relies on dozens of skilled, board-certified radiologists and supporting staff to support immediate patient care. All CTS doctors, staff and workflows follow PIPEDA, HIPAA, local regulations and other patient and technology privacy requirements. CTS radiologists specialize in MRI, CT, PET, US, NM, MAMMO, X-ray and BMD modalities and offer expertise in emergency room care.

Leveljump Healthcare’s Management Team

Mitch Geisler – CEO, Chairman

Mitch has been the CEO of CTS since 2010 and has overseen its operations and growth to one of the leaders in the Canadian teleradiology space. Mitch is a seasoned entrepreneur in multiple sectors including healthcare, mining and hospitality. Mitch has built companies from the ground up and has extensive experience in operations management and oversight. He has experience implementing policies and procedures, directing marketing and growth strategies, and providing initiatives for long term corporate success. Mitch is a graduate of York University where he earned a Bachelor of Art degree in History.

Rob Landau – CFO, Director

Rob has been working as a consultant to CTS since 2009 and became its CFO in 2019. He has advised on its operational growth and accounting matters. Rob has many years of experience with corporate finance and structuring, corporate accounting and auditing as well as working with start-up companies. Rob has a great ability to think outside the box to assist in problem solving, securing funding and creating structured corporate vision and focus. Rob has a Bachelor of Commerce degree from the University of Toronto specializing in Actuarial Science and Corporate Finance.

Sandra J. Hall – Director

Sandra Hall has provided financial, administrative and executive services to numerous publicly traded companies independently since 1996 ranging from President of EnerNorth Industries Inc., an American Stock Exchange listed company, to secretary and director of TSXV Canadian Capital Pool companies Good2Go Corp and Good2Go2 Corp. As such, Hall has extensive practice in corporate secretarial, financial administration and regulatory and investor communications for public and private companies. Throughout her career, Hall has also held various directorships and executive positions in reporting issuers including: Corporate Secretary and Comptroller of Novicius Corp.; President of EnerNorth Industries Inc; Secretary, Comptroller and Director of API Technologies Corp.; Director of TNK Resources; Special Committee Member and a Director of Quarry Oil & Gas Ltd; and a director of Rally Energy Corp. Hall has a comprehensive understanding of financial statements, accounting practices, audit committee responsibilities and reporting requirements in Canada and the United States.

Jeff Stevens – Director

Jeff is the CEO of Psyched Wellness, a Canada-based health supplement company trading on the CSE that is focused on the distribution of functional mushroom and associated consumer packaged goods. He is a seasoned capital markets and deal structuring professional who has taken several companies public, including Datametrex AI Limited, Graph Blockchain, New Wave Esports and Psyched Wellness via reverse takeovers on various Canadian stock exchanges. He has also advised on numerous M&A opportunities. Jeff has held both senior officer and director roles with public companies including: Co-Founder, President and COO of Datametrex AI Limited; Interim CEO of Graph Blockchain; Director of New Wave Esports; and Director of Global UAV Technologies.

Keep reading... Show less

HempFusion Wellness

Developing Full and Broad-Spectrum CBD Hemp Extract Production for the Consumer Markets

Overview

HempFusion Wellness Inc. (TSX:CBD.U,OTCQX: CBDHF) is a Colorado-based premium wellness company specializing in full-spectrum CBD hemp extract distribution and development, with a focus on the rapidly growing US cannabis market. The company is focused on providing innovative and diverse proprietary formulation using the power of whole-food hemp nutrition and marketing premium consumer-specific product lines across multiple distribution platforms. HempFusion is now expanding its distribution beyond its natural and e-commerce channels into doctor and practitioner networks, convenience and food-drug mass and big box retailers.

Using a proprietary Whole Food Hemp Complex™, the company offers an array of dietary supplements, including hemp-based cannabidiol (CBD), OTC topicals, capsules and other high-quality CBD products. These over 46 products are manufactured under cGMP standards designed to attain efficacy and safety and contain a broad spectrum of cannabinoids and other constituents sourced from quality phytocompounds.

With a strong background in research and development, HempFusion is at the forefront of health and wellness in the rapidly growing CBD industry. Positioned for growth, the company distributes its family of brands to approximately 4,000 retailers across 47 US states, with plans for further international expansion.

In 2020, the company began conducting the Human Safety Study for liver toxicology and completed the NOAEL Safety Review for all topicals with Self GRAS Affirmation pending. They currently have 30 products under development, including additional OTC Drug Listed Ingestibles.

HempFusion is one of the few companies marketing FDA Drug Listed Topicals in compliance with all FDA regulations. Understanding the uncertainties of an emerging industry like CBD, HempFusion is working with twelve other CBD companies to conduct a study addressing FDA concerns regarding CBD products and human safety.

Invested heavily in regulatory compliance, HempFusion prioritizes safety, quality and consistency while aiming to exceed the high standard required by retailers and consumers. This is demonstrated in the company’s U.S. Hemp Authority Certification and status as a board member of the U.S. Hemp Roundtable, an organization committed to advancing safe hemp and CBD products.

The company’s rigid approach to regulatory compliance and best practices has favorably positioned them to enter major retail, food and drug markets that are not open to other CBD companies.

With an international expansion in their sights, HempFusion CBD and Probulin Probiotic product lines are projected to be sold across Europe, distributing to Ireland and the UK first. Additionally, the company already has purchase orders for Probulin Probiotics in the Middle East, South Korea, China, Mexico, and India.

In terms of domestic prospects, the company is well on their way to getting picked up by other major vendors and has their sights on becoming a top brand in the U.S. With the recent partnership with pro snowboarder and filmmaker Travis Rice, they hope to see more brand recognition amongst target audiences. The significant time and capital invested in HempFusion’s compliance provide the company with a competitive advantage in the expanding CBD sector, which is projected to reach $16.8 billion by 2025.

As of June 2020, HempFusion Wellness reported 1,750 shareholders and $18.3 million in cash with no debt. With the second-largest cash position in the sector, the company is gearing up for a direct IPO onto the Toronto Stock Exchange senior board, where it has reserved ticker symbol CBD.U.

HempFusion’s management team holds extensive experience in public markets, finance, legal, CPG and M&A. This world-class leadership has been crucial in driving the company’s business plan forward and primes them to expand their strategic networks and revenue opportunities. Potential channels could include natural medicine, e-commerce, big box, convenience, doctor practitioner and healthcare.

HempFusion Wellness Company Highlights

Premium wellness company focused on providing innovative and diversified proprietary formulation using the power of whole-food hemp.
Armed with world-class research and developmental processes, the company is prepared to market its premium CBD product lines across multiple distribution platforms.
Offers a wide variety of CBD products that contain a broad spectrum of panoramic hemp extract, including liquids/tinctures, capsules, travel pouches and OTC topical products.
Key partnerships with Verdant Oasis and Probulin Probiotics Co. has strategically positioned the company for international expansion into European markets and medicinal distribution networks.
As of June 2020, HempFusion Wellness holds the second-largest cash position in the CBD sector, with over $18.3 million in cash and an estimated 1,750 shareholders.
In May 2021, the company entered into a Purchase Agreement to acquire 100 percent interest in APCNA Holdings LLC (“Apothecanna”), a pioneer in cannabis-powered body care and topicals and an industry leader in the development of innovative, all-natural CBD products.
Hempfusion completed the acquisition of Sagely Enterprises Inc. (“Sagely Naturals”), a leader in premium CBD products with mass distribution in more than 14,000 retailers nationwide.
Alibaba Group Holding’s Tmall Global (“Tmall”) received conditional approval to launch HempFusion’s CBD products on Tmall, the world’s largest cross border online marketplace.

HempFusion Wellness Key Products

HempFusion champions compliance and customer safety and is one of the few CBD companies approved to market FDA Drug Listed Topicals. The compliance with FDA regulations and standards ensure that these products meet the standards set by larger national retailers. In terms of compliance with international regulations, all of HempFusion’s products are made from DNA-verified, non-GMO, organic industrial hemp that has been registered in the European Union, which has a rich history spanning across decades of hemp cultivation.

HempFusion OTC Topicals

HempFusion offers a wide selection of over-the-counter (OTC) topicals that remedy condition-targeted ailments. With a focus on pain relief, skin-care and wound care specifically, clinically tested botanical complex and broad spectrum panoramic hemp extract sets HempFusion apart from other competing products on the market.

With a projected expansion into doctor and practitioner channels, HF and Biome Research product lines have shown great interest amongst integrative medical doctors and licensed chiropractors. This enthusiasm has created a higher potential for CBD companies like HempFusion to enter into these healthcare spaces early.

The company could see great success in these well-established markets. The global pain relief and dermatitis market for topicals is projected to reach $13.3 billion and $13.6 by 2026, respectively. Additionally, in 2019, the ten top-selling first aid and wound healing ointments generated over $650 million in sales in the US alone.

HempFusion CBD Product Line

With a commitment to innovation and providing premium wellness to consumers, HempFusion has created a wide variety of CBD products, including CBD liquids, capsules, travel pouch, topicals.

In partnership with Verdant Oasis, the company has exclusive access to high-quality organic European CBD oil for its CBD Tinctures. In harmony with lab-formulated whole food hemp complex, these tinctures utilize broad-spectrum DNA-verified hemp, broad-spectrum CBD and a wide array of critical compounds to create a premium product.

Today, only 15 percent of CBD penetration is seen in US households. With their multiple revenue avenues and expansion plans, HempFusion has adopted a multi-channel approach to maximize consumer and clinical reach and fill gaps in the market. The key partnership with Probulin Probiotics has opened networks into the natural health industry and retail distribution, with products addressing a wide array of consumer needs.

Along with potential roll out into big box stores, e-commerce has the potential for successful launch through convenience channels. This gateway strategy is intended to allow the company to establish, develop and build relationships among these retailers, potentially accelerating access to their CBD products in the future.

HempFusion Wellness Management Team

Jason Mitchell, N.D – Co-Founder & Co-CEO

Jason Mitchell, N.D., designs nutritional health products for humans. From an early age, he was grafted into the natural products industry. Fresh out of college, he started building one of today’s leading vitamin companies, and in the process, designed and launched more than 300 dietary supplements and related products to the market. Today, he is the co-founder of Probulin and HempFusion, two leading brands in their categories with the potential to disrupt the industry. He is a Naturopathic Doctor board certified by the American Naturopathic Medical Certification Board and a Board Member for the US Hemp Roundtable.

Ian Dequeiroz – Co-Founder & Co-CEO

Ian Dequeiroz is a serial entrepreneur with extensive experience in early-stage cannabis and hemp companies. In 2010, Dequeiroz acquired the first cannabis CO2 extraction company in the US and facilitated companies’ licensing process in numerous major cannabis markets, including; Jamaica, Illinois, New York, Nevada, and Washington. Dequeiroz was the founder of multiple cannabis companies including, Epican Medicinals Ltd., one of Jamaica’s premier cannabis companies.

Jon Visser – CRO

Jon Visser has over 25 years of experience in all areas of sales and marketing, with a proven track record of consistently driving growth across all major channels. Visser was previously the Senior Vice President of Sales at Navajo Inc., a multinational manufacturer/distributor of brands like Pennzoil Automotive Supplies, Piranha Eyewear, and Navajo Inc., the largest distributor of trial- and travel-sized health and beauty products in the United States. Visser grew annual sales from $60 million to $128 million in less than three years while at Navajo Inc.

Maria Leal – CFO

Ms. Leal holds a CPA and an MBA and has a strong track record in financial management having served in various senior financial accounting positions during her more than 20-year career. Ms. Leal has been with HempFusion since July 2019 and has been instrumental in all financial reporting aspects for the Company.

Ola Lessard – CMO

Ola Lessard brings years of experience in the CBD and hemp industry and is also the President of the U.S. Hemp Roundtable. With experience in marketing creative and effective brand strategies, Lessard has held Vice President of Marketing’s position at Barlean’s, an award-winning supplements provider based in Washington.

Nancy Angelini – Director of the Doctor/Practitioner Channel

Nancy Angelini has over 25 years as an active, licensed practitioner. Angelini travels the country as a lecturer and product manager. She is responsible for opening doors to some of the largest doctor/practitioner networks in the United States.

Daniel Brody – CCO

Daniel Brody is the co-founder and former Vice President of The Green Organic Dutchman Holdings Ltd. Brody has been instrumental in listing multiple world-class cannabis companies, including TGOD, Emblem Corp. and Plus Products Inc. Before joining the cannabis industry, he spent seven years working at two leading Canadian brokerage firms.

Keep reading... Show less

Sixth Wave Innovations

Nanotechnology Using Molecularly Imprinted Polymers (MIPs) With Multi-Market Applications

Overview

Sixth Wave Innovations (CSE:SIXW,OTCQB:SIXWF,FSE:AHUH) is a nanotechnology company that uses patented Molecularly Imprinted Polymers (MIPs) for detecting, capturing and purifying substances at the molecular level.

MIPs are synthetic polymers uniquely designed to capture and extract target materials from a background of other materials by a combination of engineered electrochemical methods to attract the materials to the polymer and templating or creating a pocket in the polymer that has the physical size and shape of the target material to ensure that only those materials are captured. Systems utilizing MIPs are developed and owned completely by Sixth Wave Innovations with multiple patented/patent pending protections in over 40 countries worldwide. With massive expertise in the chemical industry and broad vertical patents, there are huge market implications for commercial scaling and revenue opportunities.

Sixth Wave Innovations captures several verticals that can appeal to multiple industries and market segments. The most notable sectors include health and wellness and mining. Sixth Wave Innovations’ patented purification and extraction systems, including Affinity™ for cannabinoid purification and IXOS® for mining, have unique MIPs designed for each sector and individual end-users. These solution offer savings in capital expenditures and operating costs as well as higher yields affording Sixth Wave Innovations’ customers substantial upticks in profitability. This translates into the potential for more efficient and effective extraction that is more stable, less expensive and yields a purer and cleaner end product. Sixth Wave Innovations’ solutions also provide unlimited scalability, which is a challenge with current technology.

For example, this has made the company poised to replace antiquated traditional extraction methods in the cannabis production and gold mining sectors, delivering process improvements, cost savings and higher yields. With the Affinity™ extraction system, Sixth Wave Innovations has gained international interest with inquiries for installation from licensed cannabis producers for over 250 units.

This technology replaces traditional methods of purification including winterization, multipath distillation, decarboxylation, and chromatography, which involves excessive plant footprint allocation, complex instrumentation with a slow turnaround, and significant product loss. Affinity™ technology can reduce this product loss and lead to higher purity of THC and CBD while providing a simplified streamline of the traditional process of extraction at an eighth of the cost.

For gold mining, Sixth Wave Innovations has created patented technology for the isolation and separation of gold and silver. While traditional extraction methods involve activated carbon, Sixth Wave Innovations’ IXOS® is extraction based on MIPs. IXOS® offers a number of advantages over activated carbon including, lower CAPEX/OPEX, lower energy consumption, six times faster elution and recovery, higher precious metal recovery due to higher efficiency and lower attrition. This is significant as gold prices continue to rise amidst a global pandemic. Sixth Wave Innovations has repeatedly demonstrated with on-site pilot testing that it can add approximately USD$125/oz to its customers bottom line and expects its portion, based on its sales model, to be approximately 30% of that savings leaving a total revenue opportunity for Sixth Wave Innovations of USD$4.7 billion per year. With this market opportunity even modest market penetration could push the Company to a billion dollar valuation.

Sixth Wave Innovations’ MIPs also have the potential for use in medical applications, including re-thinking Personal Protective Equipment (PPE) and the detection of viruses like COVID-19. Through the development of a rapid virus detection platform using MIPs, testing could be made available through point-of-use screening at high volume, and PPE could be enhanced in its protective capabilities.

Through partnerships with NeoCon International, Centre Technologique des Résidus Industriels (CTRI) and The Natural Sciences and Engineering Research Council of Canada (NSERC), Sixth Wave Innovations is in development of both point-of-care tests and their Smart Mask™, the incorporation of virus detection technology in both N95 compliant and other masks. Moreover, since virus detection utilizing Sixth Wave Innovations’ technology will allow virtually instantaneous detection via colorimetric or electronic detection, Sixth Wave Innovations will be able to seamlessly provide integration into contact tracing systems,. Proof of concept is expected by the end of 2020, and commercialization through global rollout is planned for 2021.

Sixth Wave Innovations Company Highlights

Sixth Wave Innovations is a nanotechnology company that uses patented Molecularly imprinted Polymers (MIPs) for detecting, capturing, and releasing substances at the molecular level.
Proof of concept of Smart Mask™ is expected by the end of 2020, with a global rollout of AMIPS rapid virus detection planned for 2021.
AMIPS technology could be implemented for less than C$5, with the ultimate goal of the project to apply this platform or technology to new viral threats quickly and at mass-production levels.
Systems are developed and owned completely by Sixth Wave Innovations and protected with patented/patent pending in over 40 countries worldwide.
Sixth Wave Innovations’ IXOS® extraction based on MIPs targets specific molecules in the desired metal, eliminating the need for regeneration, which is faster, less expensive and can yield higher purity gold with the potential for more capacity.
Affinity™ technology can reduce product loss and lead to higher purity of THC and CBD while providing a simplified streamline of the traditional process of extraction at an eighth of the cost.
With extraction system Affinity™, Sixth Wave Innovations has gained international interest with inquiries for installation from cannabis producers from over 250 units.
Sixth Wave Innovations also acquired 100 percent of the outstanding common shares of Geolithic Corp, which was established in January of 2017 as a joint venture between TriLateral and Sixth Wave to exploit the latter’s technology for the extraction of lithium from geothermal brines located primarily in the Salton Sea area of California.
Sixth Wave Innovations also engages Alberta Center for Advanced MicroNanotechnology Products (“ACAMP”) to integrate Radio Frequency (“RF”) technology with the company’s Accelerated Molecularly Imprinted Polymer (“AMIPs™”) virus detection technology, to create smart prototypes such as the company’s proposed SmartMask™

Sixth Wave Innovations Key Technologies

AMIPS: MIPs for the Rapid Detection of Viruses

Sixth Wave Innovations AMIPS

In response to the global pandemic, Sixth Wave is developing a rapid single-use test can detect SARS-CoV-2 easily and on-site within seconds. Past the immediate COVID-19 threat, the ultimate goal of the project is to produce a rapid response capability so that the AMIPs technology can be utilized to address other existing and emerging viral threats.

The proposed platform would involve the detection of infection through electronic (such as radio frequency identification – RFID), colorimetric, or fluorometric methods. Here, a test strip would be exposed to breath or bodily fluid, and a simple binary (yes/no) test would rapidly indicate the presence or absence of the virus. The test would allow for high volume, point-of-use screening in the public sector, private industry, hospitals, long -term healthcare facilities, and various forms of public transportation. As a completely synthetic test there are no bottlenecks in production and no need to harvest antibodies which are still grown in animals that must be sacrificed.

Ongoing research could also lead to huge potential changes for testing styles, accuracy in the detection of antigens and viruses and how this technology can be applied to real-world situations. With implementation costs for this technology being as low as C$5, masks could help businesses/schools identify exposures visually or detect ongoing infection for lengths of time.

In early 2020, Sixth Wave partnered with NeoCon International and is currently in development of Smart Mask™, the incorporation of AMIPs for rapid virus detection into an N95- compliant, or other mask/respirators. This technology will provide enhanced protective capabilities of a mask with added interactive capability of alerting the user of the presence of the target virus in their exhaled breath.

Proof of concept of Smart Mask™ is expected by the end of 2020, with a full global rollout planned for the middle of 2021.

Sixth Wave Innovations Management Team

Jon Gluckman — President, CEO & Director

Jon Gluckman brings a 25-year track record of innovative, technology-driven achievements to his role as President of Sixth Wave. As founder and CEO of Integrated Dynamics, a government engineering services company since 1996, Dr. Gluckman focused on the development and subsequent transition of advanced technologies into commercial applications. As the leader of 6th Wave since 2012, Dr. Gluckman has concentrated his efforts to complete IXOS®, in the metals processing industry. Dr. Gluckman holds a Ph.D. from the University of Cincinnati.

Sherman McGill — Executive VP & CDO

Sherman McGill is a seasoned sales and business development executive with a documented track record of developing and closing multi-million dollar development programs (R&D), product sales and training services to high profile US and international customers. McGill is spearheading business development efforts to lead Sixth Wave into becoming one of the world leaders in Molecular Imprinted Polymer (MIP) nanotechnology.

Aristotle Kalivretenos — CSO

Aristotle Kalivretenos is responsible for new product development and commercialization of Molecularly Imprinted Polymers (MIPs) for Life Science Applications, including pharmaceuticals, natural products, food safety, healthcare and drug detection. Kalivrentenos performed a postdoctoral fellowship focusing in the CNS area at Columbia University after earning his Ph.D. in organic chemistry from Colorado State University and a BS in chemistry from Clemson University.

John Cowan — COO

John Cowan started his career as an engineering craft apprentice and additionally gained many years of relevant college education including a BS Honors Degree in Mechanical Engineering, Cowan progressively used his education and experienced gained from over 25 years with the Eaton Corporation in Europe and the USA to contribute in all levels of leadership within the operations engineering and quality disciplines.

Dr. Garrett Kraft — Vice President of Innovations

Dr. Kraft has been with Sixth Wave since July 10^th, 2017 and is spearheading multiple initiatives in the Company, including the development of the Company’s AMIPs product for pathogen detection, including the SARS-CoV-2 virus, and managing the companies Intellectual Property portfolio. Dr. Kraft earned his Ph.D. from the University of Connecticut in Polymer Science and has over a decade of polymer synthesis experience. Dr. Kraft is named as an inventor on many of Sixth Wave’s patents since joining the company.

Peter Manuel—Interim Chief Financial Officer

Mr. Manuel brings over 30 years of financial management experience, having spent 17 years in public practice as a chartered accountant and 12 years as Chief Financial Officer of Ucore Rare Metals Inc. Mr. Manuel will continue in his role as Director of Sixth Wave, in which he has served since January of 2020.

Sokhie Puar—Board of Directors

Mr. Puar, with over 30 years in the public markets, has worked in various capacities in both public and private companies in a variety of sectors, including mining, oil and gas, technology, education and clean energy. Most recently, Mr. Puar held the positions of CEO, Chairman and Director of Candelaria Mining Corp. from February 2012 to September 2017. During his tenure, Candelaria Mining Corp. raised in excess of $28 million and acquired several mining projects in Mexico. Mr. Puar is currently the Lead Director of Else Nutrition Holdings Inc., a company which he helped go public. Since going public in June of 2019, Else Nutrition has raised over $41 million. Mr. Puar also sits on the board of Adcore Inc., a technology company in the digital advertising space.

Dr. David Fransen — Board of Directors

Dr. Fransen has served on the Company’s Advisory Board since June of 2020. Dr. Fransen’s career spans 40 years in various roles including senior executive positions in government, academia and the diplomatic corps. Dr. Fransen has provided strategic leadership across a wide range of economic policy and program sectors as a senior official at the Privy Council Office and Health Canada, as an Assistant Deputy Minister at Industry Canada, as the first Executive Director of the University of Waterloo’s Institute for Quantum Computing, and as Canada’s Consul General in Los Angeles.

Keep reading... Show less

Lobe Sciences

A Leader in Transformational Medicine

Overview

Lobe Sciences Ltd. is a life sciences company focused on the research and development of psychedelic medicines. The Company focuses on clinical development of devices and medicines to treat neurological disorders and brain trauma. The Company’s mission is to identify and develop transformative new methods, medicines and devices to improve brain health and provide new pathways for treating brain injuries and neurological disorders. The Company undertakes the development of innovative medicines and devices to treat mental health disorders and improve well-being while building a growing a portfolio of intellectual property to protect our technologies. The Company is working to develop psychedelic compounds as therapeutics.

Psychedelics (serotonergic hallucinogens) are powerful psychoactive substances that alter perception and mood and affect numerous cognitive processes. They are generally considered physiologically safe and do not lead to dependence or addiction. NAC is a dietary supplement derived from the amino acid L-cysteine. Taking NAC increases the level of glutathione, a potent antioxidant and anti-inflammatory molecule, in cells. Glutathione’s function is to protect cellular compounds such as DNA and prevent damage to them from reactive oxygen species and inflammatory cytokines. It is also used as an antidote for acetaminophen overdose.

Studies indicate that no proven treatment modality currently exists for the sequelae/long term effects of either mTBI with PTSD or either condition alone. The Company’s vision is to administer the compounds of psilocybin and N-acetylcysteine (“NAC”) in doses that will be administered at home, the emergency department or clinic. The Company plans to develop psilocybin-based therapeutics in combination with NAC for the treatment of mild traumatic brain injuries (“mTBI”) and post-traumatic stress disorder (“PTSD”) and devices for the efficient application of these medications

The first focus is on micro-dosing psilocybin in combination with NAC for the treatment of mTBI and PTSD and other neurological disorders. Additionally, they may be paired with odorants to create memory odor imprint pairing. The second is micro-dosing MDMA, where MDMA is combined with NAC for the treatment of mTBI and PTSD and other neurological disorders. Likewise, pairing them with odorants in an attempt to create memory odor. Third, Lobe Sciences has been evaluating the development of a medical device for immediate delivery of medicines directly to the olfactory bulb[, the structure located in the forebrain of vertebrates that receives neural input about odors detected by cells in the nasal cavity, for best therapeutic outcomes. Finally, a virtual reality (“VR”) is often shown to be used in enhancing the therapeutic outcomes of patients. We are evaluating the use of a VR headset or a fully immersive pod combined with a nasal mist transducer device (“NMT”) to improve efficiency and raise response to treatment.

The Company has submitted a provisional and PCT patent applications and launched a preclinical research study to examine a strategy that combines two products for the treatment of PTSD and mTBI with PTSD. The proposal will use a well-established rodent model to test the use of a combination of NAC and psilocybin in animals that have been subjected to mild-moderate traumatic brain injury with PTSD induced through an established rodent PTSD paradigm.

psilocybin potential applications

Cowlitz County Cannabis Cultivation Inc., was another subsidiary of Lobe Sciences. Cowlitz, based in Washington State, is a Tier 2 licensed cannabis processor. Washington is one of the states where medical and recreational use of cannabis is legal and is one of the most mature cannabis markets in the country. As a top producer in the state, Cowlitz has a range of innovative products and brands it brings to the market. Lobe divested Cowlitz to a multistate cannabis operator called Ionic Brands.

On March 8, 2021 the company completed the sale of Cowlitz County Cannabis Cultivation Inc. to Ionic Brands Corp.

Strengthened Lobe’s balance sheet with C$1.75 million cash on closing
Lobe Sciences received 100,406,701 series E non-voting preferred shares of CNSX:IONC which convert on a one-to-one basis and carry an annual dividend of 13% for a period of two years
Lobe Sciences also received 4,000,000 five year C$0.30 Ionic Brand warrants

Lobe Sciences’ Company Highlights

Headquartered in Canada with North American Operations
Currently developing psychedelic therapeutics as an integrated biotech company
Therapeutic development focused mild traumatic brain injury(mTBI)and posttraumatic stress disorder (PTSD) associated with head trauma
Lobe Sciences is currently prosecuting several provisional patents to treat PTSD or mTBI with PTSD
Additional provisional patent for methods and compositions for treating mTBI PTSD alone with 3,4 MDMA plus NAC
patent pending for a medical device for delivery of medicines to the olfactory bulb
Lobe Sciences is collaborating with a multidisciplinary team of scientists and physicians from the University of Miami where Dr. Michael Hoffer is conducting a large preclinical study on the effect of the treatment of mTBI with PTSD or PTSD alone based on the combination of psilocybin and NAC

Lobe Sciences’ Future Outlook

Moving ahead, Lobe Sciences has a range of catalysts on the horizon.

The company is gearing up to conduct pre-clinical studies, which includes GLP toxicology, ADME in addition to forming and manufacturing, to file an investigational new drug application (IND). Lobe Sciences, together with its subsidiary Eleusian Biosciences, will partner with the University of Miami to conduct the study on rodents to prove the efficacy of the molecules.

With successful results following the study and regulatory approval, Lobe Sciences aims to file its IND with the US Food and Drug Administration (FDA) by March 2022 to be able to move the candidate of psilocybin and NAC into a Phase 3 Clinical Trial by July 2022 on humans for the treatment of mTBI with PTSD or PTSD alone in collaboration with investigators at the University of Miami and other clinical research institutions. The company aims to look at what proper dosing will look like with these trials.

Pending any FDA approval, Lobe Sciences will consider bringing its products to other global markets.

Lobe Sciences’ Management Team

Philip J. Young – CEO & Director

Philip Young is an accomplished CEO and innovative professional with 25 years of expertise in senior executive management and board roles, with significant mergers and acquisitions and equity financing experience. He has a proven track record in the biotech, medtech and pharmaceutical industries with expertise in dealing with FDA/regulatory frameworks as well as new device and therapeutics development. From 2015 until 2019, Mr. Young was the Founder, Chairman, and CEO of Exactus Inc. (“Exactus”), an OTCQB listed company he successfully transitioned from a medical technology company to a farming focused hemp-derived CBD company.

Prior to Exactus, Mr. Young was the president, CEO, and Director of AmpliPhi Biosciences Corp. (now Armata Pharmaceuticals Inc.), a global biopharmaceutical company. He was also previously the President, CEO and a director of Osteologix Inc., where he was responsible for directing and managing all facets of the global pharmaceutical development company. He is the former Chief Business Officer and Executive Vice President of Insmed Inc., where he directed all financing, corporate and commercial communications activities. Prior thereto, he was the Vice President and General Manager of Neurex Corp., where he was involved with the negotiations for its US$700 million acquisition by Elan Corporation. Mr. Young holds a Bachelor’s of Science from James Madison University.

Brian Zasitko – CFO

For over 13 years, Brian Zasikto has worked in a number of private and public companies in sectors such as cannabis, agriculture, manufacturing, and utility industries. Mr. Zasitko is well versed in financial reporting and corporate governance and the capital markets.

Dr. Maghsoud Dariani – Chief Science Officer

Dr. Dariani has extensive experience working with a wide range of life science companies. He is the current president and CEO of Semorex Inc., a privately held company focused on novel therapeutics for cancer. Mr. Dariani was previously the president of Focus Pharmaceuticals, Inc., where he managed the development and approval of drug products and notched an FDA approval for another clinical evaluation stage.

Jonathan Gilbert – Executive Director

Jonathan Gilbert was the founder and CEO at Tassili Life Sciences Corp., a biotech firm conducting research with psilocybin. Gilbert is also the founding CEO of Eleusian Biosciences, which Lobe Sciences acquired in June 2020, and will play an integral role in the company’s growth strategy moving forward.

Leighton Bocking – Director

Leighton Bocking has worked in the capital markets for over a decade. Primarily, his role has been as an independent corporate development consultant as well as other various director roles. Mr. Bocking has been particularly focused on financing and structuring companies.

Dr. Mark A. Geyer Ph.D – Scientific Advisor

Dr. Geyer is Distinguished Professor of Psychiatry and Neurosciences Emeritus at the University of California San Diego (UCSD) and directs the Neuropsychopharmacology Unit of the VISN 22 Veterans Administration Mental Illness Research, Clinical, and Education Center. He is respected internationally for his research on the psychophysiology, neurobiology, and pharmacotherapy of schizophrenia and bipolar disorder. Dr. Geyer’s broad experience as a researcher, grant reviewer, journal editor, and teacher lends invaluable scientific and professional expertise to several organizations, as he provides leadership to develop strong programs in the behavioral psychopharmacology and clinical applications of psychedelic agents.

Charles S. Grob, MD – Scientific Advisor

Charles S. Grob, M.D. is Professor of Psychiatry and Pediatrics at the UCLA School of Medicine. He previously held faculty positions at the Johns Hopkins School of Medicine and the University of California at Irvine. He has conducted approved clinical research with psychedelics since the early 1990s. From 2004-2008 he was the Principal Investigator of the first study in several decades to examine the use of a psilocybin treatment model for patients with advanced-cancer anxiety. He has also conducted research into the range of effects of MDMA, in both normal volunteers and in a selected subject population of adult autistics with severe social anxiety. And, he has conducted a series of ayahuasca research studies in Brazil. Over the last thirty years Dr. Grob has published numerous articles on psychedelics in the medical and psychiatric literatures and he is the editor of Hallucinogens: A Reader (Putnam/Tarcher, 2002), co-editor (with Roger Walsh) of Higher Wisdom: Eminent Elders Explore the Continuing Impact of Psychedelics (SUNY Press, 2005) and co-editor (with James Grigsby) of the recently published Handbook of Medical Hallucinogens (Guilford Press, 2021). He is a founding board member of the Heffter Research Institute.

Benjamin Kelmendi, MD – Scientific Advisor

Benjamin is a psychiatrist and an Associate Professor in the Department of Psychiatry at the Yale University School of Medicine. His primary clinical expertise is in PTSD, Depression, OCD, and the endocannabinoid system. He is the co-founder of the Yale Psychedelic Science Group. He leads a research program focused on the therapeutic potential of psychedelic medicines, across a range of psychiatric diagnoses. He is currently investigating the effects of psilocybin on the neurocircuitry implicated in the development, maintenance, and treatment of patients with OCD. He is also exploring the effects of MDMA on brain activation and neural network organization in PTSD to understand the relationship between MDMA-induced neural changes and the acute cognitive and behavioral effects of the drug.

Albert “Skip” Rizzo, Ph.D – Scientific Advisor

Albert “Skip” Rizzo is a clinical psychologist and Director of Medical VR at the University of Southern California Institute for Creative Technologies. He is also a Research Professor with the USC Dept. of Psychiatry and School of Gerontology. Over the last 25 years, Skip has conducted research on the design, development and evaluation of Virtual Reality systems targeting the areas of clinical assessment, treatment, and rehabilitation across the domains of psychological, cognitive and motor functioning in both healthy and clinical populations. This work has focused on PTSD, TBI, Autism, ADHD, Alzheimer’s disease, stroke and other clinical conditions. He has also driven an extensive research program on the use of intelligent virtual human agents for clinical training, healthcare information support, and clinical assessment. In spite of the diversity of these clinical R&D areas, the common thread that drives all of his work with digital technologies involves the study of how Virtual Reality simulations can be usefully applied to human healthcare beyond what’s possible with traditional 20th Century methods.

Ilan Hayman – Advisor

Ilan has played a pivotal role in the General Management of healthcare businesses including a private cosmetic surgery chain and the commercialisation of a breakthrough skincare range. He successfully led the development of these products from concept through to production commercialization. Most recently Ilan oversaw a group of national medical centers. His career into operations management was triggered by his valuable experience as part of the Risk and Controls Solutions practice at PricewaterhouseCoopers (PwC). Specifically, Ilan’s passion is assisting the medical fraternity in their practice management and business administration functions. Ilan’s ambition is to work in a role that utilises his analysis expertise enriched by his exposure to the commercial side of business. Ilan has a passion for assisting community organizations and sits on several boards of not for profit organizations. He also holds Bronze and Silver Duke of Edinburgh awards and brings along a unique set of community and industry related experience.

Bart Oates — Advisor

Bart Oates Esq. is a three-time Superbowl Champion, who graduated magna cum laude with a Juris Doctor degree from Seton Hall during his off season. Prior to his NFL career, he earned a BS in Accounting from the Marriott School of Business at BYU and was inducted into their athletic Hall of Fame in 1992. Bart was selected to five Pro Bowls during his NFL career and to the UPI All-NFC team three times. Bart is now the President of the NFL Alumni Association which offers former players a diverse package of medical, business, and legal services to help keep them and their families healthy, productive, and connected to their former teammates.

Gilberto Jesús Mendoza – Advisor

Gilberto Jesús Mendoza is currently the President of the World Boxing Association. Mr. Mendoza began his career as a lawyer and an engineer and has been working with the WBA since 2015. His priority has always been to give opportunities to the most vulnerable regions of the world. He has spent time in close contact with athletes since he was a child and has actively participated in the intention to rescue amateur boxing. Mr. Mendoza is the proud creator of “Un Solo Boxeo” (Only One Boxing), a program that promotes the integration of professional boxing. He also created the Future WBA Champion, a project that has given space to thousands of boxers in their preparation stage for the Tokyo Olympic Games. Mr. Mendoza’s goal is the growth and development of boxing, as well as its adaptation to change.

Keep reading... Show less

Asia Green Biotechnology

Optimizing CBD-Rich Hemp For Emerging Applications

Overview

Asia Green Biotechnology Corp (CSE:ASIA) is an agricultural technology corporation focused on the creation, cultivation, production and application of high-quality and specialized hemp strains in emerging Asian markets. The company is focused on five emerging use applications of hemp and hemp by-products: food, fibre, fuel, pharmaceutical and foundational materials. Driven by the global trend towards the legalization of cannabis, a new awareness of the versatility and viability of products derived from hemp is increasingly causing use of the plant and its by-products to be considered in a number of industrial applications.

Asia Green intends to pursue this opportunity by developing and offering a diverse range of hemp strains and hemp-derived products. In cooperation with its technical partners, the company is working to develop its organic hybridization technology which has the potential to lead to the development of new hemp-based products tailored for specific applicationss. Initially, Asia Green has established cultivation partnerships with a particular focus on Cambodia and Thailand in pursuit of low-cost cultivation conditions that have the potential to facilitate optimal hemp crop growth.

According to research conducted by Research and Markets, the global industrial hemp market is expected to grow at a compound annual growth rate of 34 percent from US$4.6 billion in 2019 to US$26.6 billion by 2025. The Asia Pacific region accounted for the largest amount of industrial hemp production in 2018, partly due to the area’s reliance on hemp as an input in the textile and paper industries. Asia Green believes the temperatures and balanced intervals of sunlight in certain regions of Asia are optimal for hemp cultivation, providing another potential competitive advantage over similar hemp producers.

As a renewable source material, hemp has the potential to reduce costs in industries capable of incorporating the plant into existing compounds and formulations. Asia Green is currently focused on developing strains that can be cultivated for specific needs including hemp-based foods, fibers, fuels and foundation materials. The company has secured a licensing agreement with InPlanta Biotechnology, a research and development team based in Alberta. InPlanta operates a state-of-the-art cannabis and hemp research and development facility in collaboration with research partners, licensed producers and government agencies at the University of Lethbridge.

Asia Green Biotechnology has also entered into an agreement with Swysh Inc, an Alberta company conducting cannabinoid-based research. The company owns proprietary technology and intellectual property related to the creation of topical treatments for a variety of ailments, including anti-viral and preventative healthcare applications. Under the terms of the agreement, Asia Green is participating in R&D activity based on Swysh’s intellectual property, enabling the company to test and market products derived from this research in the company’s licensed territories.

“Through the InPlanta license agreement, we have seen ACC expand its business activities in Asia in a positive way. By entering this license agreement with Swysh, we believe the Company will be in a position to significantly expand that activity with access to potential cannabinoid-based treatments and other elements which have the potential to be of significant benefit to populations of the region,” said Dr. Igor Kovalchuk, director of Asia Green. Dr. Kovalchuk is also a director and the controlling shareholder of Swysh.

Asia Green Biotechnology’s Company Highlights

Proprietary organic hybridization technology allows for strains to be bred to produce specific traits optimized for common use-cases
Partnered with InPlanta Biotechnology to develop hemp strains optimal for use as food, fuel, fiber, and foundation materials
Global industrial hemp market expected to grow from US$4.6 billion in 2019 to US$26.6 billion by 2025 according to Research and Markets
Asia Pacific region accounted for the largest amount of industrial hemp production in 2018
Licensing agreement with Swysh, enabling Asia Green to participate in R&D activity based on Swysh’s intellectual property

Swysh Partnership

In March of 2020 Asia Green Biotechnology announced a licensing agreement with Swysh Inc., a research and development team based in Alberta. Under the terms of the agreement, Asia Green has been granted a license to deploy Swysh’s proprietary technology and intellectual property for the purpose of research, development, testing and further validation of potential applications.

asia green biotechnology research and development

“Swysh and its partners continue to actively research and develop the protocols and, by extension, specialised treatments, associated with these new cannabinoid lines, extracts and their related applications. In addition to the domestic research programs we are implementing, we hope to expand on the network being developed by ASIA in Asia to continue the thorough research and development process on the use of hemp extracts for prevention of SARS-CoV2 infection, especially at a time when such significant need exists for preventative and therapeutic treatments for COVID-19,” said Swysh CEO Dr. Igor Kovalchuk, who also operates as a director at Asia Green.

InPlanta Agreement

Asia Green has also secured a licensing agreement with InPlanta Biotechnology, a research and development team based in Lethbridge, Alberta. Under the terms of the agreement, Asia Green has the right to access the intellectual property and associated research and development information gained by InPlanta at its University of Lethbridge facility in southern Alberta.

The InPlanta research center includes greenhouses, breeding rooms and labs to facilitate the continued optimization of its proprietary strains. The company works with research partners including licensed producers, government agencies, and private companies such as Asia Green. InPlanta has already developed an extensive catalog of strains available to its partners, including high-CBD hemp strains with significant potential for industrial hemp products.

Moving forward, Asia Green intends to work in partnership with both Swysh and InPlanta to improve its hemp varieties, optimizing strains to produce specific qualities in accordance with the growing use cases for medical, nutritional and industrial hemp. By using the data available to Asian Green through its partnerships, the company intends to leverage its organic hybridization technology while developing new products for the hemp market.

Asia Green Biotechnology’s Management Team

David E.T. Pinkman — President, CEO and Director

David Pinkman BA, LLB, founded, operated and was Executive Chairman of Jupiter Power International Inc., an independent power production company which successfully built and operated a number of power plants in Cambodia and SE Asia. Mr. Pinkman has participated in the management and ownership of a number of companies in his recent career. Previously, he was the Interim Chief Executive Officer of Synstream Energy Corp., a corporation specializing in the application of gas-to-liquids technology in the oil industry, from August 21, 2017 until December 29, 2017 and served as a director from May 2007 until present. He is the Chief Financial Officer and a director of International SoftRock Oil Company Limited, an oil and gas E&P firm which had operations in West Africa, and has been so since February 2015. He is and has been a director of Builders Capital Mortgage Corp. since March 28, 2013. Mr. Pinkman has served on the boards of a variety of local volunteer organizations, and continues to serve as a director and Treasurer of Wild Rose Motocross Association and is a director of the Canadian Motorcycle Association.

Johannes J. Kingma — Director

Mr. Kingma is a self-employed businessman who has served as CEO of a private investment company (2006 – ) and President, Chairman, and a Director of Synstream Energy Corp. (TSX-V:SHM), since 2007. He has also served as director and officer of a number of private and public companies (2004 – 2010). Prior to this, Mr. Kingma was a Partner, sales manager and investment advisor with IPO Capital Corp., and was similarly a registered investment advisor with Canadian Western Capital Limited.

Vincent E. Ghazar — Chief Financial Officer and Director

Mr. Ghazar has served CFO and Director of Asia Cannabis Corp. from early 2018. Mr. Ghazar has a professional accounting practice (2014 – ), is the Controller of Synstream Energy Corp. (2013 – ), and CFO and VP Finance of Standard Exploration Ltd., both public companies. He has advanced training in compliance, regulatory and governance practices and has extensive IFRS and GAAP experience.

Igor Kovalchuk, Director

Mr. Kovalchuk has served as an Asia Cannabis Corp. Director since mid-2018. He is the co-founder of Inplanta Biotechnolgy Inc. (est. 2015), founder of genomics company Plantbiosis ( est. 2010), and a (co)founder of Pathway Rx (est. 2016). Presently, he is a Professor and the Board of Governors Research Chair at the University of Lethbridge, Department of Biological Sciences (2001 – ) and Board of Governors’ Research Chair in Plant Biotechnology (2007 – ). He is also an executive member and Scientific Leader of Alberta Epigenetics Network (2014 – ), and a Director of Next Generation Sequencing Facility (2010 – ).

Dr. Darryl Hudson, P.H.D, Director

Dr. Hudson is a principal of InPlanta Biotechnology Inc. and received a PhD in Molecular Biology and Genetics from the University of Guelph in 2010. He has published research in diverse fields including plant biology, genetics, epigenetics, DNA repair mechanisms, and carcinogenesis. He primarily works as a consultant and researcher helping producers in many countries to optimize genetics, cultivation processes and quality assurance protocols in the cannabis industry.

Keep reading... Show less

Sirona Biochem Inc.

Advanced Chemistry Platform for Commercial Opportunities in Cosmetics and Pharmaceuticals

Overview

Sirona Biochem Inc. (TSXV:SBM) is a biotechnology company with an innovative platform for developing safer, more effective cosmetic and pharmaceutical active ingredients. The technology is based on proprietary fluorination chemistry developed by the company’s wholly-owned French subsidiary, research and development (R&D) laboratory TFChem. Sirona Biochem’s business model centers on leveraging its technology platform and chemistry expertise to build strategic R&D partnerships with leading global companies through contract services, licensing and royalty agreements as well as joint ventures.

TFChem has developed a fluorination chemistry that can improve the safety and efficacy of carbohydrate-based molecules. Carbohydrate-based molecules are valuable in that they have broad application potential for the development of pharmaceuticals and cosmeceuticals. Examples of commercially available carbohydrate-based drugs include viral neuraminidase inhibitor Tamiflu, and Johnson & Johnson’s (NYSE:JNJ) SGLT2 inhibitor Invokana™. However, carbohydrate-based molecules are extremely challenging to develop due to their inherent instability. Sirona Biochem’s proprietary chemistry technique overcomes that challenge by stabilizing carbohydrates, allowing the company to explore commercial opportunities for these valuable molecules.

Sirona Biochem’s product pipeline includes an SGLT2 inhibitor for the treatment of type 2 diabetes as well as cosmeceuticals such as compound libraries for safe and effective skin lighteners and anti-aging compounds. The company has completed two successful licensing agreements. The first, for its SGLT2 inhibitor to Wanbang/Fosun Pharmaceutical in China, which is now in advanced Phase I clinical trials. The second was a non-exclusive license to Rodan + Fields, the leading skin care brand in the United States, for Sirona’s skin lightening compound TFC-1067. The compound has proven safe and effective in clinical trials.

Sirona Biochem is led by a highly experienced team of finance and biotechnology professionals. The company’s Chief Scientific Officer Dr. Géraldine Deliencourt-Godefroy is an award-winning synthetic chemist and the founder of the French biotechnology company TFChem. Her scientific research in carbohydrate chemistry has led to the discovery of new drug families and the development of drug candidates for diabetes and obesity, cosmetic ingredients and biological adjuvants. She is the recipient of the acclaimed Francinov Research and Innovation Medal, the French Ministry of Research Award and the French Senate Award.

Keep reading... Show less

Numinus

Innovative Research into Psychedelic Therapies

Overview

Numinus (TSXV:NUMI, OTC Pink: NUMIF) is a healthcare company at the forefront of addressing the growing prevalence of mental health issues and desire for greater wellness. The company offers an integrated therapeutic model to create lifelong relationships with people seeking physical, mental and emotional health with a focus on treating mental illness, trauma and substance abuse.

In addition to services including counselling, neurofeedback, physiotherapy and other therapies, Numinus aims to conduct psychedelic-assisted therapies to help people heal, connect and grow — when approved by Health Canada, Colleges and other regulators. Numinus put a value chain in place that will be key to the company's growth and success. Numinus Bioscience is licensed by Health Canada to test, sell and distribute psychedelic substances. Numinus Wellness plans to establish physical locations where psychedelic-assisted therapies can take place once approved by regulators. Lastly, Numinus R&D is where partnerships with leading research groups will take place to advance practice and understanding in the space.

numinus lab

Numinus Bioscience is making a name for itself in analytical testing for psychedelic substances and as a place of excellence for product research and development. Numinus Bioscience's 7,000 square foot analytics and research laboratory handles a range of psychedelic substances and analytical methods and uses for the psychedelics space. In October 2020, Numinus announced it had harvested the first legal flush of Psilocybe mushrooms in Canada by a public company under its Health Canada-issued Controlled Drugs and Substances Dealer's Licence.

Numinus was founded by Payton Nyquvest and Stacey Wallin, who both have a passion for developing holistic therapies that deal with the root causes of mental illness, addictions and trauma. The two founders have a wealth of experience in bringing innovative companies to the capital markets. Nyquvest, for example, has raised over C$100 million for public and private companies alike and has facilitated numerous IPOs, including Numinus' pending RTO with Salvation Botanicals and Rojo Resources Ltd. Joining the team as Chief Operating Officer is Michael Tan, who was the first director for the British Columbia Liquor Distribution Branch's (BCLDB) cannabis division. He also has a track record of driving profitable revenue growth.

Numinus' Company Highlights

RTO with Salvation Botanicals and Rojo Resources Ltd. completed in Q2 2020.
When approved by Health Canada and Colleges, Numinus aims to conduct psychedelics-assisted therapies to help people heal, connect and grow. These therapies will be conducted in safe, controlled therapeutic environments when approved by regulators.
Has a 7,000 square foot laboratory that is licensed by Health Canada to test, possess, buy and sell various controlled substances.
In October 2020, the company harvested the first legal flush of Psilocybe mushrooms in Canada by a public company under its Health Canada-issued Controlled Drugs and Substances Dealer's Licence.
Revenue from the company's existing cannabis testing operations provides a foundation for growth, differentiating Numinus from others in the psychedelics space.
The cannabis portion of the business has the potential to bring in C$25 million, dependent on timing of receiving Health Canada processing licence and production facility operating at capacity.
The company's long-term plans are to build a network of healing centres across North America, staffed with professional therapists and integrative health professionals.
Research partnerships in place with MAPS and Together We Can and Memorandum of Understanding signed with the BC Centre on Substance Use (BCCSU).
Numinus has closed its acquisition of the Neurology Centre of Toronto (NCT), a leading Canadian provider of clinical neurologic care.

numinus lab

Regulators Turning to Psychedelic Therapies to Treat Mental Illness and Addiction

In 2017, psychedelic therapies were designated as a breakthrough therapy by the FDA due to the growing need for solutions for mental health-related issues across the globe. According to the World Health Organization, mental health disorders affect one in four people at some point in their lives, and approximately 450 million people currently suffer from mental health issues, making it a leading cause of ill-health and disability worldwide.

If left untreated, mental health disorders can cost Canadians C$51 billion per year in health care costs, lost productivity and reductions in health-related quality of life, according to the Centre for Addiction and Mental Health (CAMH).

Leading organizations such as the FDA and Johns Hopkins are helping to position the use of psychedelic assisted therapies in regulated, safe, controlled therapeutic environments as accepted therapeutic options. Many research organizations, such as BCCSU, have been testing the efficacy of treating mental health disorders with various psychedelics.

Numinus' Management Team

Payton Nyquvest – Founder, Chairman and CEO

Payton Nyquvest founded Numinus out of a lifelong interest in health, wellness and personal development, triggered by mental health and chronic autoimmune problems in his earlier years. Transformational therapies helped to save his life, and he is driven to provide public access to these therapies.

He is a former Director, VP and Head of Sales at Mackie Research Capital, with 15 years of experience focusing on early-stage companies in multiple industries including technology, healthcare, biotech, cleantech and cannabis. He has raised over $100 million for more than 100 public and private companies and facilitated numerous IPOs.

Dr. Evan Wood – Chief Medical Officer

Dr. Evan Wood is a recognized researcher with 20+ years of experience in addiction research, most recently as Executive Director of the British Columbia Centre on Substance Use (BCCSU). A professor of medicine at the University of British Columbia. Work on psychedelic-assisted psychotherapy, his work includes involvement with the Multidisciplinary Association for Psychedelics Studies (MAPS) trial of MDMA-assisted psychotherapy and examining the potential of psilocybin-assisted psychotherapy for a range of mental health disorders.

Dr. Devon Christie – Medical Director

Dr. Christie, a clinical instructor with the UBC Department of Medicine, is also a family physician with a focused practice in Multidisciplinary Pain Management. She is a Registered Therapeutic Counsellor emphasizing Relational Somatic Therapy for trauma resolution and she is also trained to deliver both MDMA-assisted psychotherapy for PTSD (MAPS USA) and ketamine-assisted psychotherapy, in a research setting. She is a recognized speaker and expert on the potential for incorporating psychedelic assisted therapies in an improved health care model for the future.

Michael Tan – Chief Operating Officer

Michael Tan is the former and first executive director of the BCLDB's Cannabis Division, where he successfully launched cannabis operations in British Columbia. Michael has 20 years of strategic planning and execution with national and multinational corporations. He is a high-impact product development, marketing and operations executive with a track record of driving profitable revenue growth.

Kraig Docherty – Chief People Officer

Kraig Docherty has over 20 years of experience growing and scaling tech and creative companies such as EA, Activision Blizzard, Indochino, Invoke and Eventbase.

John Fong – Chief Financial Officer

John Fong is a professional accountant with over two decades of experience in financial and operational management. He provides stability and growth solutions to public natural resource companies and technology start-ups.

Dennis McKenna – Advisor

McKenna brings over 40 years of experience conducting research in ethnopharmacology. He is a Founding Board Member of the Heffter Research Institute and a former key investigator on the Hoasca Project, the first biomedical investigation of ayahuasca. McKenna has taught courses on Ethnopharmacology and Plants in Human Affairs for 17 years as an adjunct Assistant Professor in the Center for Spirituality and Healing at the University of Minnesota . In collaboration with colleagues in Canada and the US, he incorporated a new non-profit, the McKenna Academy of Natural Philosophy.

Jamie Wheal – Advisor

Wheal is a bestselling author, Pulitzer Prize nominee and founder of the Flow Genome Project, an international organization dedicated to research and training of ultimate human performance. Since its inception in 2011, the organization has become the leading voice of evidence-based peak performance. Wheal is an expert on peak performance and leadership, specializing in the neuroscience and application of Flow states.

Ben Nemtin – Advisor

Nemtin is the #1 New York Times bestselling author of What Do you Want to Do Before You Die?, co-founder of the Buried Life movement and a mental health advocate. Nemtin was forced to drop out of university due to depression and in an effort to feel more alive, he and his three friends made a list of “100 things to do before you die" and for every list item they accomplished, they helped a complete stranger cross something off their bucket list. Oprah Winfrey declared their mission “truly inspiring." Nemtin is recognized as one of the “World's Best Motivational Speakers" as well as “World's Top Organizational Culture Thought Leaders" by Global Gurus and regularly speaks to Fortune 100 leadership teams and business conferences around the world.

Pamela Hadfield – Advisor

Hadfield is an entrepreneur and thought leader in the cannabis space. She became a cannabis advocate after finding relief from debilitating migraines using medical cannabis. After cannabis transformed her health, she dedicated her time and efforts to helping others with alternative healthcare approaches, including cannabis. Hadfield is the co-founder of HelloMD, a digital telehealth and educational platform for cannabis consumers and people seeking complementary care.

Nichol Bradford – Advisor

Bradford is CEO of the Willow Group and Executive Director of the Transformative Technology Lab. She is a former senior executive in the video game industry responsible for strategy, operations and marketing for major brands, including Disney, Vivideni and Activision Blizzard. Bradford is also a fellow of the British American Project, a former term member of the Council on Foreign Relations and served on the board of the Brandon Marshall Foundation for Mental Health.

Keep reading... Show less

NeonMind Biosciences

NeonMind Biosciences Inc manufactures Medicinal Mushroom products under the brand NeonMind which are for sale through e-commerce on its website. It is also in the early stages of development of a product with the goal of using such product to promote and cause weight loss using a compound found in psychedelic mushrooms. The company’s product …

Cardiol Therapeutics

Clinical-stage biotechnology company focused on developing innovative therapies for inflammatory heart disease

Overview

Cardiol Therapeutics Inc. (TSX: CRDL) (NASDAQ: CRDL) is a clinical-stage biotechnology company focused on developing innovative therapies for inflammatory heart disease. The Company received approval from the U.S. FDA for its Investigational New Drug (IND) application and has commenced the LANCER Study, a Phase II/III, double-blind, placebo-controlled clinical trial investigating the efficacy and safety of its lead product, CardiolRx™, in hospitalized COVID-19 patients with a prior history of, or risk factors for, cardiovascular disease. CardiolRx™ is an ultra-pure, high concentration cannabidiol oral formulation that is pharmaceutically produced, manufactured under cGMP, and THC-free (<10 ppm).

Cardiol is planning a Phase II international trial of CardiolRx™ in acute myocarditis, a condition caused by inflammation in heart tissue, which remains a leading cause of sudden cardiac death in people less than 35 years of age. The Company is also developing proprietary cannabidiol formulations for the treatment of inflammation in the heart that is associated with the development and progression of heart failure. Heart failure is the leading cause of death and hospitalization in North America, with associated annual healthcare costs in the U.S. alone exceeding $30 billion.

In collaboration with researchers and opinion leaders at international centers of excellence, including the Houston Methodist DeBakey Heart & Vascular Center and TecSalud del Tecnológico de Monterrey, Mexico, Cardiol is leveraging multidisciplinary expertise in drug delivery, drug formulation, cardiac physiology, and heart failure. The Company’s research collaborations provide Cardiol with the optimal platform on which to pursue the commercial development of new therapies for chronic heart failure, a leading cause of death and disability in the western world.

The Company’s management team has extensive experience in the research and commercial development of novel therapeutics. Additionally, insiders and employees are notably invested in the Company, holding approximately 16 percent of the outstanding shares.

Cardiol Therapeutics’ Company Highlights

Leadership position in cannabidiol-based cardioprotective therapies
Lead clinical programs targeting large opportunities in inflammatory heart disease
Strong scientific rational for developing cannabidiol (CBD) as an anti-inflammatory agent
Proprietary oral formulation in Phase II/III LANCER Study
IND application accepted for Phase II trial assessing tolerability of CardiolRx in acute myocarditis patients

LANCER, a Phase II/III COVID-19 Trial

On April 28, 2021, Cardiol announced the enrollment of the first randomized patient in the LANCER trial, a Phase II/III, double-blind, placebo-controlled clinical trial investigating the efficacy and safety of CardiolRx™, a pharmaceutically produced extra strength cannabidiol formulation, in 422 hospitalized COVID-19 patients with a prior history of, or risk factors for, cardiovascular disease (CVD). The trial is taking place at major centers in the United States, where the prevalence of COVID-19 remains high.

Patients with COVID-19 primarily present with respiratory symptoms which can progress to bilateral pneumonia and serious pulmonary complications. It is now recognized that the impact of COVID-19 is not limited to the pulmonary system. Individuals with pre-existing CVD or who have risk factors for CVD (such as diabetes, hypertension, obesity, abnormal serum lipids, or age greater than 64) are at significantly greater risk of developing serious disease from COVID-19 and experience greater morbidity. Moreover, such COVID-19 patients are at significant risk of developing cardiovascular complications (such as acute myocardial infarction, cardiac arrhythmias, myocarditis, stroke, and heart failure) during the course of their illness, and which are frequently fatal, with an estimated 30 – 40% of patients who die from COVID-19 doing so from cardiovascular complications. A strategy to prevent or limit the number or severity of these cardiovascular complications is likely to considerably improve outcomes from this disease.

Cardiol’s LANCER trial has been designed to assess the efficacy, safety, and tolerability of CardiolRx™ in preventing cardiovascular complications in hospitalized patients, with a confirmed diagnosis of COVID-19 within the previous 24 hours, and who have pre-existing CVD and/or significant risk factors for CVD. The composite primary efficacy endpoint will be the difference between the active and placebo groups in the percentage of patients who develop, during the first twenty-eight days following randomization and first dose of study medication, a composite endpoint consisting of one or more of several common outcomes in this patient population, including all-cause mortality, requirement for ICU admission and/or ventilatory support, as well as cardiovascular complications, including the development of heart failure, acute myocardial infarction, myocarditis, stroke, or new sustained or symptomatic arrhythmia.

“There is compelling evidence that inflammation plays a fundamental role in the development and progression of heart disease,” said Dr. Andrew Hamer, Chief Medical Officer of Cardiol Therapeutics. “I am excited to see the initiation of the LANCER trial which will provide a unique opportunity to explore the anti-inflammatory and cardioprotective properties of CardiolRx in COVID-19 patients who are at high risk for major cardiovascular complications.”

Orphan Drug Program for Acute Myocarditis

In June 2019, Cardiol announced its intent to complete an international clinical trial for acute myocarditis, an inflammation of the heart muscle commonly caused by a viral infection of the heart tissue, utilizing its CardiolRx CBD formulation

The most recent data from the “Global Burden of Disease Study” suggests that the prevalence of myocarditis is approximately 22 per 100,000 population, qualifying the condition as an orphan disease in the U.S. and in Europe. Orphan Drug programs in the U.S. and EU are eligible for accelerated marketing approvals and other incentives, including a prolonged period of market exclusivity.

“The U.S. orphan drug program was successfully utilized to accelerate the first FDA approval of CBD for the treatment of rare forms of pediatric epilepsy and significant shareholder value was created in the process,” stated Cardiol President and CEO David Elsley. “Given the mortality and significant morbidity risk associated with acute myocarditis, we believe there is a similar opportunity in pursuing an expedited development program of our CardiolRx pharmaceutical CBD formulation for this serious orphan disease which has no accepted standard of care.”

Although the symptoms are often mild, myocarditis remains an important cause of acute and fulminant heart failure and is a leading cause of sudden cardiac death in people less than 35 years old. In addition, some patients proceed to develop chronic dilated cardiomyopathy which continues to be the leading indication for cardiac transplantation. Symptoms include chest pain, fatigue, shortness of breath, and arrhythmias. Because of the progressive damage to heart cells, heart failure develops (defined as the inability of the heart to pump sufficient blood to meet the needs of the body).

In November 2019, Cardiol announced the formation of the Clinical Steering Committee (CSC) for a Phase II international trial in acute myocarditis using the CardiolRx™ CBD formulation. The CSC is expected to provide oversight of the protocol, including amendments and advice to investigators regarding all aspects of the trial.

The CSC is comprised of nine highly distinguished thought leaders in cardiology from the Cleveland Clinic, the Mayo Clinic, the Houston Methodist DeBakey Heart and Vascular Center, the University of Ottawa Heart Institute, McGill University Health Centre, the University of Pittsburgh Medical Center, Tampa General Hospital Heart and Vascular Institute, and Charité University Medicine Berlin.

In April 2020, Cardiol announced topline results from a Phase I single and multiple ascending dose clinical trial of CardiolRx™. Topline results demonstrated that CardiolRx was safe and generally well tolerated at all dose levels, with no serious adverse events reported in the study. The findings were consistent with published results for oral cannabidiol formulations and serve as a rationale for the dosing regimen that will be utilized in the Company’s planned Phase II program in acute myocarditis.

In August 2021, Cardiol announced that the U.S. Food and Drug Administration (FDA) provided clearance to proceed with the Company’s Investigational New Drug (IND) application to commence a Phase II, multi-center, double-blind, randomized, placebo-controlled trial designed to study the safety and tolerability of CardiolRx™, as well as its impact on myocardial recovery in patients presenting with acute myocarditis.

Cardiol’s acute myocarditis study is expected to enroll 100 patients at clinical centers in the United States and Europe. The primary endpoints of the trial, which will be evaluated after 12 weeks of double-blind therapy, consist of the following cardiac magnetic resonance measures: left ventricular function (ejection fraction and longitudinal strain) and myocardial edema (extra-cellular volume), each of which has been shown to predict long-term prognosis of patients with acute myocarditis.

Cardiol Therapeutic’s Heart Failure Program

People with heart failure suffer from a variety of ailments, including shortness of breath, rapid heart rate, edemas, reduced exercise capacity, can often struggle with simple daily activities, and are frequently hospitalized. Many of these symptoms can significantly reduce the quality of life for an individual.

There are two types of heart failure: systolic and diastolic. Systolic heart failure, or heart failure with reduced ejection fraction (HFrEF), occurs when the left ventricle cannot adequately pump blood from the heart and into circulation. Diastolic heart failure, or heart failure with preserved ejection fraction (HFpEF), occurs when the left ventricle becomes stiff and doesn’t relax as it should and, as a result, cannot fill properly, causing pressure to build in the left side of the heart and in the lungs. This results in a patient feeling shortness of breath and is associated with health concerns such as obesity, hypertension, and diabetes.

Another complication that can be experienced by those suffering from HFpEF is chronic inflammation, which can lead to a decrease in blood vessel function, impairment of heart muscle function, and fibrosis, which results in stiffness in the heart and a reduction in pumping efficiently. Over the past 20 years, there have been little to no significant treatments developed for HFpEF, as therapies have primarily remained focused on diuretics.

The Market

More than 26 million people across the globe are affected by chronic heart failure. Of this number, six million are based in Canada and the U.S., making heart failure a leading cause of death and hospitalization in the region. In the U.S. alone, the associated health costs exceed $30 billion annually.

To combat the effects of heart disease and to create a better quality of life for patients, Cardiol is developing a proprietary subcutaneous formulation of cannabidiol to achieve higher bioavailability than an oral formulation. This subcutaneous formulation would be a new approach to the treatment of chronic heart failure based on the anti-inflammatory activity of cannabidiol to treat inflamed heart tissue and the anti-fibrotic activity of cannabidiol to treat fibrosis (scarring) in heart muscle.

Published third-party research has shown that cannabidiol reduces inflammatory activation of the endothelial lining of blood vessels and aids endothelial vasorelaxation, resulting in improved blood flow. Cannabidiol has also been shown to attenuate a number of measures of inflammation in models of diabetes, a common co-morbidity in heart failure patients, and to reduce myocardial fibrosis in a model of inflammatory heart disease.

Cannabidiol is lipid soluble, virtually insoluble in water, highly sensitive to deactivation in the liver via first-pass metabolism when taken orally and is rapidly cleared from the body. This results in a low overall bioavailability of less than 10% when taken orally. Cardiol’s subcutaneous administration of cannabidiol is designed to minimise first-pass metabolism, optimize and maintain blood levels of the drug, and target inflammation and increased fibrosis in the heart. Cardiol believes that overcoming the low bioavailability issues associated with cannabidiol will significantly broaden the therapeutic potential of this molecule.

Cardiol Therapeutic’s Strategic Partnership

Dalton Pharma Services

Cardiol has established an exclusive manufacturing arrangement with Dalton Pharma Services (Dalton) for the supply of pharmaceutical cannabidiol for Cardiol’s research programs using CardiolRx™

Located in Toronto, Canada, Dalton is a Health Canada approved, FDA registered, cGMP manufacturer of over 200 Active Pharmaceutical Ingredients (APIs), including pharmaceutical cannabinoids, with manufacturing capability scalable to support all stages of the regulatory process (Phase I, II, III and commercial). In 2016 and 2017, Dalton Pharma Services received the Leadership Award for Contract Manufacturing Organizations (CMO) in the following categories: Quality, Capabilities, Expertise, Compatibility and Development.

Dalton is also the manufacturer of Nabilone, the largest prescription pharmaceutical cannabinoid in the world, with annual sales of $100 million in Canada alone.

As part of the partnership, Dalton is also a significant shareholder in Cardiol. Dalton’s founder, owner and CEO, Peter Pekos, is on Cardiol’s board.

Cardiol Therapeutic’s Research Collaborations

DeBakey Heart and Vascular Center

Cardiol is conducting experimental research at the Houston Methodist DeBakey Heart & Vascular Center, designed to investigate the activity of the Company’s proprietary subcutaneous cannabidiol formulation in a model of heart failure.

The Houston Methodist DeBakey Heart & Vascular Center is recognized internationally as a center of excellence for the treatment of heart failure. The center was the birthplace of cardiovascular bypass surgery in 1964 and is currently ranked the 14th best hospital for care in cardiology and heart surgery out of 5,028 hospitals in the United States.

TecSalud del Tecnológico de Monterrey

Cardiol is collaborating with TecSalud del Tecnológico de Monterrey (TecSalud) on research and development of a proprietary subcutaneous cannabidiol formulation for the treatment of heart failure. The primary objective of this collaboration is to develop the experimental evidence necessary to support advancing breakthrough treatments for heart failure into clinical development.

TecSalud has collaborative relationships with the Houston Methodist DeBakey Heart & Vascular Center and the University of Calgary and has established a formal agreement with the Massachusetts Institute of Technology (MIT) to promote research and development in science and technology in Mexico.

Cardiol Therapeutics’ Management Team

David Elsley, MBA – President, CEO and Director

Founder and CEO of Vasogen Inc., with 25 years of experience developing, financing and managing all aspects of corporate development of biotechnology and high-growth organizations.

Andrew Hamer, MB, ChB – Chief Medical Officer

Former Executive Director at Amgen Inc., responsible for leading global development for Repatha®, former Chief Cardiologist at Nelson Hospital, New Zealand. 19 years of experience practicing Cardiology and Internal Medicine.

Chris Waddick, MBA, CPA, CMA – Chief Financial Officer

Thirty years of experience in financial and executive roles in the biotechnology and energy industries, former Chief Financial Officer and Chief Operating Officer of Vasogen Inc.

Anne Tomalin, BA, B.Sc., RAC – Director of Regulatory Affairs

Founder of CanReg Inc and TPIreg, regulatory firms previously sold to Optum Insight and Innomar Strategies respectively. An expert in regulatory affairs in Canada, United States and Europe.

Andrea B. Parker, MSc, PhD – Director of Clinical Affairs

Chief Scientific Officer at Peter Munk Cardiac Centre, University Health Network. Clinical Epidemiologist with more than 30 years’ experience in clinical trials design, management, and execution in industry and academic settings.

Dolly Kao, BSc, JD – Intellectual Property Counsel

Co-Founder of PCK LLP. Highly experienced IP lawyer with a practice focused primarily on patent and trademark matters (procurement, oppositions, and opinions) for clients in the chemical, pharmaceutical, and biotechnology industries.

Anthony E. Bolton, B.Sc., Ph.D., D.Sc. – Director of Research

Immunologist, 20+ years of experience in biotechnology, Chief Scientific Officer of Vasogen Inc.; former Professor and Department Head of Biomedical Sciences, Sheffield, UK.

Blagoja Ristevski, B.Sc., CHE – Director of Chemical Engineering and Manufacturing

Chemical Engineer, 25+ years of experience in the biopharmaceutical industry, senior exec. roles in eight Canadian biopharmaceutical Co.’s in the research/discovery of drug products; VP Product Dev., AMRIC Institute, Ontario, Canada.

Board of Directors

Guillermo Torre-Amione, MD, Ph.D. – Chairman

President of TecSalud academic medical center and school of the Instituto Tecnológico y de Estudios Superiores de Monterrey (ITESM), Mexico. Former director of Cardiac Transplantation at the Houston Methodist DeBakey Heart & Vascular Center.

Peter Pekos, B.Sc., M.Sc. – Director

President, CEO and Founder at Dalton Pharma Services with broad experience in the research, development and commercialization of pharmaceuticals, products and services.

David Elsley, MBA – President, CEO and Director

Founder and CEO of Vasogen Inc., with 25 years of experience developing, financing and managing all aspects of corporate development of biotechnology and high-growth organizations.

Iain Chalmers, BA, BEd, MBA – Director

Professor of Marketing at Centennial College Business School. Former Vice-President Marketing and Innovation at Diageo, the world’s largest spirits company. Over 25 years’ experience in consumer products with Gillette and Procter & Gamble.

Colin Stott – Director

Thirty years of experience in pre-clinical and clinical development, with specific expertise in the development of cannabinoid-based medicines. Currently Chief Operating Officer of Alinova Biosciences Ltd. and former Scientific Affairs Director, International and R&D Operations Director for GW Pharmaceuticals plc, a world leader in the development of cannabinoid therapeutics.

Michael J. Willner, Esq. – Director

Michael J. Willner, Esq. has practiced as both an Attorney and a Certified Public Accountant. He graduated from Emory University Law School as a member of the Emory Law Review. Subsequently, he practiced real estate and corporate law with New York City-based Milbank, Tweed, Hadley & McCloy, one of the nation’s most prominent international law firms. Prior to his legal career, Mr. Willner was employed by the former Arthur Andersen & Company, a national accounting firm, where he practiced in Arthur Andersen’s tax department.

Mr. Willner has been a very active and successful opportunistic investor for over forty years and is the founder of Willner Capital, Inc., an investment company specializing in public and private equities, as well as debt instruments. Willner Capital primarily uses fundamental analysis as an evaluation method and event-driven strategies. Over the past ten years, Willner Capital has made significant investments in both the biotechnology and pharmaceutical cannabinoid industries, focusing primarily on clinical-stage companies that seek to address significant unmet medical needs. Mr. Willner has been quoted in the New York Times business section and has served as a moderator and participant on numerous panel discussions and advisory boards regarding his investments in the pharmaceutical end of the cannabinoid industry.

Advisors

Steven Grasso

Mr. Grasso began his career on the floor of the New York Stock Exchange in 1993. He joined Stuart Frankel & Co. as an institutional sales trader in 1999. As Director of Institutional Sales for Stuart Frankel & Co., Steven has worked closely with some of the largest mutual funds, pension funds, insurance companies, and hedge funds in the world directly from the floor of the Stock Exchange. Over his 27-year career, Steven has actively participated in various Stock Exchange committees ranging from allocating new listings to designated market makers to developing standardized tests that the floor community uses for continuing education. Steven closely follows the Washington D.C./Markets connection, using his extensive Capitol Hill and SEC relationships to better inform his clients on policy changes and regulation.

Steven is perhaps best known for being a CNBC market analyst and is a regular on CNBC’s popular “Fast Money” show, which airs daily during the business week and has an average daily viewership that currently exceeds 250,000. Mr. Grasso also speaks at many traders’ conferences across the country on a regular basis, as well as business round tables with many influential leaders of industry where he addresses a broad range of market related issues, including the effects of regulation and the political process on equities.

Keep reading... Show less

BriaCell

Developing Personalized Off-The-Shelf Immunotherapy Treatments for Cancer Patients

Overview

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, TSXV:BCT) is a biotechnology company with a mission to develop innovative immunotherapies for treating cancer and infectious diseases.

At the forefront of cancer treatments, immunotherapies boost the ability of the body's own cancer-fighting cells to destroy cancerous tumors. Immunotherapies also have low-toxicity, making it easier for patients to undergo treatment. Most importantly, they may offer better efficacy and less chance of recurrence for many cancer patients. In a report released by Research and Markets, the global immuno-oncology market is expected to reach $100 billion by 2022, and BriaCell continues to uncover opportunities in this space with its innovative technologies.

BriaCell's lead candidate, Bria-IMT™, is an immunotherapy currently being developed to treat advanced breast cancer, which is the expected cause of approximately 43,000 deaths in the US in 2021. Bria-IMT™ recently achieved positive proof of concept, showing outstanding safety and efficacy data. Importantly, preliminary efficacy data was similar or superior to those of other approved breast cancer drugs when they were at a similar stage of clinical development.

BriaCell currently has a non-exclusive clinical trial collaboration with Incyte Corporation (NASDAQ:INCY) to evaluate the effects of combinations of novel clinical candidates. Under the agreement, Incyte and BriaCell will be evaluating novel combinations of compounds from Incyte's development portfolio with BriaCell's drug candidates in advanced breast cancer patients.

BriaCell has been dosing patients in a Phase I/IIa clinical trial of Bria-IMT™ in combination with the immunotherapy development candidates retifanlimab, an anti-PD-1 antibody, and is planned to also combine with epacadostat, an orally bioavailable small-molecule inhibitor of indoleamine 2,3-dioxygenase 1 (both provided by Incyte). The combination study is listed in ClinicalTrials.gov as NCT03328026.

BriaCell is also developing Bria-OTS™, an off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS™ immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS™, which is expected to match over 99 percent of the patient population, is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense and complex manufacturing logistics associated with other personalized immunotherapies.

In November 2020, BriaCell announced a Cooperative Research and Development Agreement with the National Cancer Institute (NCI, Center for Cancer Research), part of the National Institutes of Health, to investigate novel off-the-shelf personalized therapeutics for cancer.

BriaCell's management team is comprised of a team of experienced industry leaders involved in the approval of dozens of drugs.

BriaCell Therapeutics' Company Highlights

BriaCell has truly emerged in the last 13 months:

April 2021: Closing of Over-Allotment Option in Connection with U.S. Public Offering, Bringing Total Gross Proceeds to US$28.7 Mil
February 2021: BriaCell Announces Closing of US$25 Mil Public Offering
November 2020: BriaCell Announces Collaboration with the NCI
October 2020: Survival Data: 13.3 months vs. 7.2-9.8 months
January 13, 2020: Remarkable Responder Update
January 9, 2020: Additional 'Biomarker' identified; Possible predictor of high-responding patients
October 7, 2019: First patient dosed under Incyte Corporation collaboration

The Cancer Immunotherapy Space

There are a number of challenges that cancer immunotherapy treatments face. Approved immunotherapies work in 20 to 30 percent of patients. They depend on the patient's weakened immune system and, in some cases can cause autoimmune disease.

Other challenges include the lack of effectiveness of cancer immunotherapies to treat some solid tumors or blood cancers since they only work in certain types of cancer and not in others. Additionally, newly developed effective personalized immunotherapies such as PROVENGE® and CAR-T need to be individually manufactured for each patient. This means a complex and time-consuming manufacturing process, which is extremely expensive and might make the therapies commercially unsuccessful.

In response to these challenges, BriaCell is developing Bria-OTS™, an off-the-shelf personalized immunotherapy, for advanced breast cancer, which has been estimated to be the cause of about 43,000 deaths in the US in 2021.

The off-the-shelf approach means that the treatments are pre-manufactured and the patient will be able to receive her or his personalized, targeted treatment using an easy and common HLA test on her or his saliva sample. This approach is quick, and relatively inexpensive, and avoids the complex manufacturing process associated with other personalized immunotherapy treatments. This approach is the first of its kind for advanced breast cancer.

Bria-IMT™

Bria-IMT™, BriaCell's lead product candidate, is derived from a specific breast cancer cell line. It is genetically engineered to release granulocyte-macrophage colony-stimulating factor (GM-CSF), a substance that activates the immune system. BriaCell believes that Bria-IMT™ helps the body to stimulate cancer-fighting T-cells, cells that directly attack tumor cells, and B-cells that produce anti-tumor antibodies.

BriaCell Bria IMT

Proof-of-concept clinical trials

The first clinical trial used the original unmodified breast cancer cell line, with low dose cyclophosphamide and GM-CSF to boost the immune response. Fourteen patients were treated and produced impressive results, including no severe drug-related side-effects and a median survival rate in patients after treatment of about twice what was expected.

The second clinical trial used Bria-IMT™ (i.e. the original cell line – modified to produce GM-CSF) along with low dose cyclophosphamide and interferon-alpha in four advanced-stage cancer patients. The treatment was tolerated very well with few side effects. The median overall survival was much longer than expected. The study also had one patient that responded extremely well to the treatment with an approximately 90 percent tumor reduction in breast cancer as well as disappearance of the cancer from the lungs and soft tissues.

Briacell Clinical Trials Source: BriaCell Therapeutics Corp.

After the treatment stopped, as required by the study, the patient's breast cancer returned and had spread to the patient's brain, lungs and other sites. Importantly, the patient was treated again with Bria-IMT™ and the tumors were reduced at multiple sites, even in the brain. This patient-matched Bria-IMT™ for HLA genes which are used to match patients to tissues in tissue transplantation (e.g. for kidney transplants).

Recent clinical findings (Phase I/IIa proof-of-concept study with Bria-IMT™: 2017 to 2018)

BriaCell completed a Phase IIa study of Bria-IMT™ in advanced breast cancer in 23 patients that were heavily pre-treated (listed in ClinicalTrials.gov as NCT03066947) and released their initial data in September 2018. To date, Bria-IMT™ treatment has been safe with several instances of tumor reduction observed in certain patients sharing a key biomarker (HLA match) with Bria-IMT™. The treatment was safe and well-tolerated. Most importantly, initial efficacy data was similar or superior to those of other advanced or approved drugs for breast cancer when they were at a similar stage of clinical development.

Based on the recent findings related to the mechanism of action of Bria-IMT™, and the potential to produce intensified anti-tumor activity when used in combination with certain drugs, the company is now conducting the combination study of Bria-IMT™ with retifanlimab and epacadostat. The combination study is listed in ClinicalTrials.gov as NCT03328026.

Immune checkpoint inhibitors such as anti-PD-1 including pembrolizumab (KEYTRUDA®; manufactured by Merck & Co., Inc.) and, more recently, Incyte's retifanlimab (under a corporate collaboration with Incyte Corporation) , are designed to neutralize immune suppression in cancer patients. The significance of immune checkpoints has been recognized by the Nobel committee by awarding Drs. Honjo and Allison with the 2018 Nobel Prize in Physiology or Medicine. BriaCell believes that Bria-IMT™ can exert additive or synergistic tumor-directed effects with checkpoint inhibitors like KEYTRUDA®. Initial safety data for the combined approach shows that it is very safe and well-tolerated by patients. Early efficacy data for the first eleven advanced breast cancer patients dosed with Bria-IMT™ in combination with KEYTRUDA® suggested strong additive or synergistic effects on tumor regression (shrinkage).

BriaCell hypothesizes that checkpoint inhibitors act by “awakening" a component of the immune system, while Bria-IMT™ “puts the foot on the gas" of the immune system, which may lead to more powerful anti-tumor activity.

BriaCell Therapeutics' Collaboration with Incyte Corporation

In April 2019, BriaCell and Incyte Corporation formed a non-exclusive clinical trial collaboration to evaluate the effects of combinations of novel clinical candidates. Under the agreement, Incyte and BriaCell plan to evaluate novel combinations of compounds from Incyte's development portfolio with Bria-IMT™ in advanced breast cancer patients.

BriaCell initiated dosing patients with advanced breast cancer in its Phase I/IIa clinical study for Bria-IMT™ in combination with Incyte's retifanlimab and epacadostat. The goal of the program is to remove cancer-induced suppression of the immune system (taking the “foot off the breaks" that cancer puts on the immune system) and stimulating an immune response with the Bria-IMT™, putting the “foot on the gas". This is expected to allow the immune system to attack the cancer in a targeted way with the help of Bria-IMT™. The combination study is listed in ClinicalTrials.gov as NCT03328026.

BriaDX™

BriaCell has developed a companion diagnostic test that would allow a physician to prepare a personalized pre-made treatment for each patient based on the presence of certain biomarkers (HLA type). Testing is simple and done on the patient's saliva.

This diagnostic test may be used in future clinical trials to speed up the clinical development of Bria-IMT™ and will be used in trials of Bria-OTS™.

Bria-OTS™

The Bria-OTS™ treatment is based on pre-manufactured immunotherapies – each containing a specific HLA type – which can be selectively administered to patients based on the patient's HLA type. BriaCell is developing 15 unique HLA types that will allow for the treatment of over 99 percent of advanced-staged breast cancer patients. This approach provides customized cancer immunotherapy for each individual patient that doesn't require personalized manufacturing.

BriaCell Bria OTS

Source: BriaCell Therapeutics Corp.

A simple diagnostic test, BriaDX™, will determine the appropriate off-the-shelf immunotherapy for each patient. Based on the results, one or two pre-made Bria-OTS™ immunotherapy cell lines will be selected to be administered to the patient. Thus, Bria-OTS™ is expected to provide the patient with fast, inexpensive, safe and effective personalized cancer immunotherapy treatment that can be ordered readily.

BriaCell Therapeutics' Small Molecule Program

BriaCell's small molecule program includes the development of novel, selective protein kinase C delta (PKCδ) inhibitors which have shown potent activity in a number of pre-clinical models of several different cancer indications as well as fibrotic diseases. Protein kinase C delta (PKCδ) inhibitors may provide another shot on goal besides a potential partnership opportunity.

BriaCell Therapeutics' Management Team

William V. Williams, MD, FACP, President & CEO, Director

Former VP, Exploratory Development, Incyte Corporation
Former VP, Experimental Medicine, GlaxoSmithKline
Former Head, Rheumatology Research, University of Pennsylvania
Extensive drug development experience

Gadi Levin, CA, MBA – CFO and Corporate Secretary

CFO of Labstyle Innovations Ltd
VP of Finance for two Israeli investment houses in the fields of private equity, hedge funds and real estate
Financial Consultant, various firms
Accountant, Arthur Andersen

BriaCell Therapeutics' Board of Directors

Jamieson Bondarenko, CFA, CMT, Chairman of the Board

Previously Principal and Managing Director of the Equity Capital Markets group of Eight Capital
Previously several positions at Dundee Securities Ltd., including Managing Director, Director, Vice President and Associate

Vaughn Embro-Pantalony, MBA, FCPA, FCMA, CDir, ACC, Director

Current: Chair, Board of Directors, Soricimed Biopharma Inc.
Board and Audit Committee Member, Microbix Biosystems Inc.
VP, Finance & CFO, Teva Novopharm Limited
VP, Finance & Administration, Bayer Healthcare
Director, Finance and Administration & CFO, Zeneca Pharma Inc.

Marc Lustig — Director

Investor, entrepreneur, and corporate finance veteran with a deep understanding of the life sciences industry, including biotechnology and pharmaceuticals, as well as the legal cannabis industry.
Holds MSc and MBA degrees from McGill University and his professional experience includes working at Merck & Co.,
His capital markets career includes roles in biotech equity research, corporate finance and as Head of Capital Markets.
Founder and CEO of Origin House where he currently serves as a director.
Director of a number of public companies, and founded the Lustig Family Medical Cannabis Research & Care Fund of the Cedars Cancer Foundation that provides cannabis to palliative cancer patients.

Martin Schmieg, CPA, Director

Current: CEO, ClearIT, LLC
CFO: Sirna Therapeutics, Inc., & Isolagen, Inc.
CEO, Freedom-2, Inc. (now PharmaCyte, Inc.)
Advisor, Caladrius Biosciences, Inc., Beckman Coulter Genomics, Calimmune, Inc., Cryoport, Inc., Vetbiologics, a division of U.S. Stem Cell, Inc., Sapientia Pharmaceuticals, Inc., & Rokk3r Labs, LLC

Rebecca A. Taub, MD, Director

Current: CMO & EVP, Director, Founder, Madrigal Pharmaceuticals
Senior VP, VIA Pharmaceuticals
VP of Research, Metabolic Diseases, Hoffmann-La Roche Company
Executive Director, Bristol-Myers Squibb
Executive Director, Dupont Pharmaceuticals
Professor of Genetics and Medicine, University of Pennsylvania

Jane Gross, Ph.D., Director

Chief Scientific Officer and SVP, Research and Non-Clinical Development at Aptevo Therapeutics (Nasdaq: APVO)
VP, Applied Research and Non-Clinical Development at Emergent BioSolutions (NYSE: EBS)
VP, Immunology Research at ZymoGenetics
Independent Director for aTyr Pharmaceuticals (Nasdaq: LIFE)

Suzanne Ostrand-Rosenberg, Ph.D. - Advisor

40 years of experience leading investigations focused on the immune system's response to cancer.
Robert & Jane Meyerhoff Professor of Biochemistry, Emeritus
Professor of Biological Sciences, Emeritus, University of Maryland Baltimore County, Baltimore, MD, and has been working with the University since 1977.
Adjunct Professor of Pathology, Huntsman Cancer Institute (HCI), University of Utah, Salt Lake City, UT, in 2018.

BriaCell Therapeutics' Management Team

William V. Williams, MD, FRCP, President & CEO

Seasoned biopharmaceutical executive with over 35 years of industry and academic expertise, including significant clinical management in multinational pharmaceutical companies.
Served as VP of Exploratory Development at Incyte Corporation from 2005 – 2016.
Facilitated entry of over 20 compounds into the clinic, including approvals for ruxolitinib (Jakafi) and baricitinib (Olumiant).
Responsible for establishing proof-of-concept in several therapeutic areas
Involved in numerous new drug applications (NDAs) for therapeutics that achieved marketing authorization

Gadi Levin, CA, MBA, CFO & Corporate Secretary

Appointed as BriaCell Therapeutics Corp.'s Chief Financial Officer in February 2016.
Acted as Chief Financial Officer of Labstyle Innovations Ltd, a biotechnology company focused on diabetes.
Served as the Vice President of Finance and Chief Financial Officer for two Israeli investment houses in the fields of private equity, hedge funds and real estate (2008 to 2009 and 2010, respectively).

Miguel A. Lopez-Lago, Ph.D., Senior Director, Research and Development

Working as a cancer scientist at Memorial Sloan-Kettering Cancer Center, New York (MSKCC).
Investigated various aspects of tumor biology, including the development of targeted therapies for Mesothelioma and the characterization of the biological mechanisms underlying cancer metastasis.
Interested in the study of the tumor immune-microenvironment and in the development of immunotherapies for thoracic cancers using chimeric antigen receptor (CAR) T cell technologies.
Since 2013, Dr. Lopez-Lago has been working as Senior Research Scientist at MSKCC. Dr. Lopez-Lago received his Bachelor of Science in Bio-Sciences and his doctorate in Molecular Biology from Santiago of Compostela University, Spain.

Keep reading... Show less

Overview

Addiction doesn't just affect 1 in 5, it affects everyone.

What is Ibogaine?

Universal Ibogaine's Company Highlights

Kelburn Addiction and Mental Health Treatment Center

Clear Sky Recovery Clinic

Universal Ibogaine's Management Team & Board of Directors

Dr. Rami Batal, PharmD/PhD - Chief Executive Officer

Greg Leavens, CPA - Chief Financial Officer

Dr. Ian Rabb - Chief Clinics Officer

Dr. Glenn Copeland - Senior Medical Advisor

Chief Ian Campbell, MBA - Chairman (Independent)

Dr. Alberto Sola, BSc, MD

Robert Turner, ICD.D, MBA - Director (Independent)

Marilyn Loewen Mauritz, ICD.D, JD - Director (Independent)

Anthony DeCristofaro - Director

David Danziger, CPA, CA - Director

Near Term Goals and Milestones

Overview

Technologies

Solarvest BioEnergy’s Company Highlights

Solarvest BioEnergy’s Key Products

Eversea

Solarvest BioEnergy’s Management Team

Gerri Greenham — CEO and Director

Dr. Azoy Kumar Kundu — Senior Research Scientist

Garth Greenham — COO

Dr. Michael Thomas Horne BA Ph.D. FRSB FCIM FIBMS CBiol CSci CMgt — Head of Research

Overview

Boosh Plant-Based Brands’ Company Highlights

Plant-Based Brands’ Key Products

Boosh Bowls

Boosh Pouches

Plant-Based Brands’ Management Team

Connie Marples – Founder, Director & President

Jim Pakulis – Director, CEO & Chairman

Ali Samei – VP Operations / Consultant

Maria Hussaini – CPA, Director & CFO

Dave Richardson – Special Advisor

Overview

Levitee Labs' Company Highlights

Levitee Labs' Integrated Wellness Portfolio

Clinic and Pharmacy Acquisition Strategy

Sporeo Supply – Mushroom Cultivation

Levitee Labs' Management Team

Pouya Farmand – CEO & Co-Founder

Kelly Abbott – COO & Director

Mason M. Darabi – CFO

Ken Osborne – CFA, Head of M&A, Co-Founder

Dr. Mohammed Mosli – Chief People Officer (Levitee Clinics, Alberta)

Marc Momeni – Executive VP

Fady Hannah-Shmouni – Chief Medical & Scientific Officer

Azim Qazi – Head of Ecommerce and Consumer Packaged Goods

Noha ElSayed - Executive Director Levitee Clinics & Levitee Pharmacies, Alberta Region

Overview

Avricore Health’s Company Highlights

Avricore Health’s Management Team

Hector Bremner – CEO

David Hall – Chairman and Director

Kiki Smith – CFO

Rodger Seccombe – Head of HealthTab™ Division

Overview

Awakn Life Sciences' Company Highlights

Awakn Life Sciences' Complementary Divisions

Awakn Research

Awakn Development

Awaken Clinics

Awakn Partnerships

Awakn Life Sciences' Management Team

George Scorsis – Chairman of the Board

Anthony Tennyson – CEO

Dr. Ben Sessa – CMO

Stephen Page – Non-executive Director

Prof. John Papastergiou – Non-executive Director

Jonathan Held – Chief Business Officer

Kate Butler – Chief Financial Officer

James Collins – COO

Shaun McNulty – CSO

Prof. Celia Morgan – Ketamine Lead

Dr. Laurie Higbed – Lead Psychologist